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ABSTRACT 
 
Obesity has become a growing epidemic that has greatly increased the 
prevalence of a variety of metabolic syndromes, such as type II diabetes, cardio 
vascular diseases, and non-alcoholic fatty liver disease. A major factor that links 
adiposity to systemic metabolic dysfunction is the resident immune cells in the 
adipose tissue that exhibit enhanced inflammatory and oxidative stress 
characteristics. In order to uncouple obesity from these diseases, it is paramount 
to understand the molecular events that control the inflammation associated with 
the adipose tissue. The expression of the fatty acid-binding protein 4 (FABP4) in 
macrophages has demonstrated to be a key determinant of inflammation and 
oxidative stress where ablation of macrophage FABP4 is protective against 
obesity related disorders. Furthermore, this decrease in macrophage 
inflammation was shown to be dependent on the upregulation of uncoupling 
protein-2 (UCP2) and sirtuin-3 (Sirt3). Collectively these proteins maintained 
mitochondrial and endoplasmic reticulum homeostasis through redox balance 
and increased levels of intracellular monounsaturated fatty acids. This further 
lowered the level of reactive oxygen species, cysteine oxidation and 
inflammatory cytokine production, all of which have been linked to metabolic 
dysfunction. The work herein provides greater mechanistic insight into the 
induction of low-grade, chronic inflammation observed with obesity, which 
ultimately provides exciting potential for new therapeutic targets.  
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Obesity induced inflammation and macrophage polarization 
 
 
 
 
Written by Kaylee Steen  
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FINANCIAL AND HEALTH BURDEN OF OBESITY 
Through genetic factors, increased prevalence of the western-style diet and a 
sedentary lifestyle, obesity has become an annual $147 billion burden on the 
United State’s health care system (data based on 2016 CDC statistics). While 
obesity is typically preventable with proper diet and exercise, for the 200 billion 
overweight individuals around the globe, prevention is only part of the solution 
(1). In order to uncouple the health care costs from the obese state, the 
mechanisms leading to obesity-related diseases need to be determined. This 
includes aberrant cellular signaling events associated with the adipose tissue, as 
this is the epicenter in which systemic disease results.  
 
From a whole body perspective, a high caloric diet increases blood glucose 
concentration, which in turn triggers pancreatic secretion of insulin where it binds 
to the insulin receptor expressed on myocytes and adipocytes. Upon ligand 
binding, the insulin-signaling cascade activates the translocation of Glut4 to the 
plasma membrane and subsequent glucose uptake in adipocytes. While this 
signaling process maintains blood glucose homeostasis, it can also lead to 
nutrient overload in the tissue as excess glucose is converted to lipids through 
citrate metabolism. These lipids are stored in the form of triglycerides, which can 
be hydrolyzed to free fatty acids in times of nutrient deprivation in a process 
called lipolysis. However, as an adipocyte begins to expand from continual lipid 
synthesis, the cell is exposed to a variety of stress conditions, including hypoxia 
and apoptosis (2, 3). This cellular stress leads to insulin resistance, and once the 
adipocyte can no longer sense insulin, lipolysis will be activated and free fatty 
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acids are released even under nutrient rich conditions. Circulating fatty acids can 
accumulate in other organs as well as initiate a variety of systemic signaling 
cascades, collectively termed lipotoxicity (4).     
 
IMMUNITY AND THE ADIPOSE TISSUE 
Inflammatory signaling is one such signaling event that is enhanced in obese 
adipose tissue, as a wide range of immune cells are recruited to the tissue by 
free fatty acids and cytokines, such as monocyte chemotactic protein-1 (MCP-1) 
and leukotrienes (Figure 1). The presence of these inflammatory immune cells 
include, but are not limited to, T cells, neutrophils, eosinophils and macrophages, 
all of which have demonstrated to regulate the metabolic homeostasis of the 
adipose tissue (5-9). Depending on the physiological state of the adipocytes and 
the biomolecules secreted from them, these immune cells can either be anti-
inflammatory or proinflammatory, which greatly contributes to the metabolic fate 
of the adipose tissue (10).  
 
These secretory factors are released by the adipocytes (i.e. fatty acids or 
cytokines) as well as resident immune cells that are already present in the tissue. 
In either case, cells respond to the local stress environment of the tissue and 
initiate signaling cascades. It is the regulation of these signaling events that can 
be the tipping point in metabolic health or disease, within the context of obesity 
(11, 12). Interestingly, it is estimated that around one-third of the obese 
population maintains metabolic health, and it is believed to be due to a reduced 
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inflammatory state in these individuals, particularly in relation to the macrophage 
population. It is therefore conceivable that by determining the inflammatory 
pathways that are activated in adipose tissue macrophages, the underlying 
causes of obesity-related diseases can be prevented (Figure 1). 
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Figure 1. Adipocyte and macrophage signaling in obese adipose 
tissue. Expanding adipocytes secrete free fatty acids (FFAs) as well as 
other chemoattractants recruit macrophages to the adipose tissue and 
polarize the cells to an inflammatory state. The proinflammatory cytokines 
secreted by the macrophage are sensed by the adipocyte and can lead to 
insulin resistance (image adapted from A. Hertzel).  	
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Macrophages are innate immune cells that are most commonly known for their 
ability to phagocytose pathogens and present the resulting antigen to T cells. 
What is less appreciated is the wide variety of macrophage phenotypes that 
exist, which allow the cells to fine tune their activity based on physiological need. 
Encompassing all these different characteristics, macrophages can be broadly 
classified into M1 (classically activated) and M2 (alternatively activated) states 
with opposing inflammatory phenotypes (13).  
 
M1 macrophages exhibit inflammatory characteristics through elevated levels of 
reactive oxygen species (ROS) and cytokines, such as interleukin-1 beta (IL-1β) 
and tumor necrosis factor-alpha (TNFα). The production of these and other 
inflammatory factors have all been strongly linked to insulin resistance and type II 
diabetes (14-16). On the other hand, M2 macrophages are associated with lean 
and, or metabolically healthy adipose tissue. In fact, M2 macrophages have been 
shown to promote metabolic homeostasis by producing anti-inflammatory factors, 
such as catecholamines and IL-10 that maintain insulin sensitivity (17). What is 
particularly incredible about macrophages is the plasticity in which they respond 
to their local environment by polarizing between an M1 and M2 state. These 
observations were supported using in vitro experiments that demonstrated gene 
expression profiles of cultured 3T3-L1 adipocytes and macrophages were altered 
when treated with conditioned media of the other cell type, respectively (18). This 
further demonstrates the potential consequences obesity can have on cellular 
function (19, 20).  
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An efficient mechanism that enables macrophages to quickly respond to local 
signals is through modulation of their metabolism. An M2 macrophage is typically 
longer lived than M1 macrophages, and therefore utilizes oxidative 
phosphorylation and fatty acid oxidation for its primary fuel sources. This is 
associated with a tightly packed and order cristae of the mitochondria that 
prevent electrons from prematurely moving into the matrix and reacting with 
oxygen. However, when a macrophage receives an inflammatory stimulus, the 
cristae become dispersed and the electron transport chain complexes become 
disorganized. This not only increases aerobic glycolysis and lactate production, 
but it also elevates the production of ROS (19, 21).  
 
Another outcome of metabolic reprograming is the accumulation of intermediate 
metabolites. For example, succinate is a TCA cycle metabolite that accumulates 
under inflammatory stimuli and inhibits the pryolyl hydroxylases thereby 
stabilizing the hypoxic inducible factor-1 alpha (HIF-1α) (22). This transcription 
factor upregulates inflammatory cytokines (i.e. IL-1β) and enzymes involved in 
glycolysis (further enhancing aerobic glycolysis). Another essential metabolite 
that accumulates during inflammatory metabolic reprogramming is itaconate. 
This molecule is synthesized by immune responsive gene 1 using cis-aconitate 
as its substrate and has been shown to prevent mitochondrial substrate level 
phosphorylation. However, itaconate is also an essential resolving agent of 
macrophage inflammation as knockout of Irg1 exhibited an increase in IL-1β and 
IL-18 expression (22, 23). These data collectively highlight the essentiality of a 
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dynamic metabolic network in order for macrophages to respond to a 
physiological or pathological state.  
 
FABP4 EXPRESSION AND MACROPHAGE POLARIZATION 
Of the many molecular events that lead to macrophage polarization, the 
expression of the fatty acid-bind 4 (FABP4) has demonstrated to play a critical 
role. This 15 kDa cytoplasmic protein binds to non-esterified long chain fatty 
acids in a one-to-one stoichiometry in order to shuttle the fatty acids inter- and 
intracellularly (24). The importance of FABP4 in metabolic homeostasis was first 
determined over twenty years ago by studying the whole body FABP4 knockout 
(AKO) in C57BL/6 mice. When put on a high fat diet, the AKO mice became as 
obese as wild type mice, but they did not develop insulin resistance (25, 26). 
Furthermore, when crossed with the atherosclerosis Apo/E mouse model or 
when given an allergen challenge, AKO mice continued to exhibit protection 
against these inflammatory-linked diseases (27, 28). It is now suggested this 
phenotype is due to the adipose tissue macrophage profile in that these 
macrophages exhibit an M2-like polarization (29). Due to the vast clinical 
implications these observations have, the last twenty years have been dedicated 
to uncovering the mechanistic role of FABP4 signaling in macrophages.  
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MACROPHAGE INFLAMMATION AND OXIDATIVE STRESS 
Inflammatory macrophages play a critical role in producing cytokines and 
reactive oxygen species. Both molecules are essential in propagating signaling 
events, and the two have intersecting yet distinct functions. Of the pathways that 
upregulate cytokine expression, the nuclear factor kappa B (NF-κB) is one of the 
most central pathways. NF-κB is basally localized to the cytoplasm through 
complex formation with IκBα (nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha), which masks the NF-κB nuclear localization 
signal. NF-κB can be relived of this inhibition through activation of toll-like 
receptor 4 (TLR4) by ligands, such as lipopolysaccharide (LPS) and saturated 
fatty acids. Once the inflammatory signal is received, IκB kinase (IKK) will 
phosphorylate and promote the degradation of IκBα, allowing NF-κB to 
translocate to the nucleus and upregulate inflammatory associated genes. Many 
of these cytokines, such as TNFα, are secreted and signal to local adipocytes, 
which further activates the NF-κB pathway in these cells (30-32). 
 
One consequence of activating the NF-κB pathway in adipocytes is the 
expression of stress kinases, such as JNK (c-Jun N-terminal kinase) and ERK 
(extracellular signal-regulated kinase). The upregulation of JNK and ERK have 
strong implications in the development of insulin resistance through serine 
phosphorylation of the insulin receptor substrate 1 (IRS1). IKK has also been 
shown to phosphorylate IRS-1 at serine residues, which ultimately signals for the 
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degradation of IRS-1 and prevents insulin-dependent glucose uptake in 
adipocytes (12, 33, 34).  
 
In macrophages, NF-κB also targets the proteins that form the inflammasome 
complex, which is a major inflammatory signaling node in immune cells. The 
inflammasome proteins include NLRP3 (NACHT, LRR and PYD domains-
containing protein 3), pro-caspase-1, ASC and pro-IL-1β. Signals, such as LPS, 
are considered to be priming events that increase inflammasome protein 
concentrations in the cytoplasm. Once this occurs, an activation signal is 
required, such as ATP, ROS, β-amyloids and other factors (35, 36). Whether 
these factors act as direct or indirect ligands for the NLRP3 receptor, the 
downstream event that follows is the self-cleavage of pro-caspase-1, which in 
turn cleaves pro-IL-1β. Secretion of IL-β leads to systemic effects, such as beta-
cell exhaustion of the pancreas that inhibits insulin release (14, 16).  
 
Reactive oxygen species is another hallmark of inflammatory macrophages. 
There are multiple locations where ROS is produced, and the local accumulation 
of ROS has different consequences. For instance, ROS produced by NADPH 
oxidase occurs in the cytoplasm and facilitates elimination of pathogens. This is a 
major source of the antimicrobial capability of macrophages in which both ROS 
and reactive nitrogen species (RNS) are synthesized. Another source of ROS 
production is in the mitochondria that results from both physiological and 
abnormal oxidative phosphorylation (37).  
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Under physiological conditions, the mitochondria will produce a basal level of 
superoxide anion due to unpaired electrons entering the mitochondrial matrix and 
reacting with oxygen. This is quickly metabolized to hydrogen peroxide by 
superoxide dismutase and further converted to water by antioxidants, such as 
peroxiredoxin 3 (38, 39). However, when a macrophage receives an 
inflammatory signal, the dynamics of the electron transport changes such that 
elevated levels of superoxide anion is produced. This ultimately leads to an 
increase in total ROS levels, with hydrogen peroxide being of particular 
importance. Hydrogen peroxide can initiate signaling events though oxidation of 
protein cysteine residues (40). Furthermore, hydrogen peroxide has a longer 
half-life compared to the other ROS members and can therefore diffuse out of the 
mitochondria and oxidize cytoplasmic proteins. This oxidation event constitutes 
one mechanism in which cells propagate signal transductions. In fact, cellular 
processes, such as cell differentiation and insulin secretion require acute bursts 
of ROS (40, 41). However, a sustained and elevated production of ROS can lead 
to cellular dysfunction through protein unfolding, apoptosis, reactive lipid 
aldehyde production as well as sustained activation of the NF-κB and 
inflammasome pathways (29, 40, 42-45).  
 
REACTIVE OXYGEN SPECIES AND CELLULAR SIGNALING 
Between the physiological and pathological roles of ROS, hydrogen peroxide is a 
major contributor to both, primarily through the oxidation of cysteine residues. 
While cysteine residues do not represent a large percentage of the amino acid 
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sequence for a protein, it is overrepresented in catalytic sites and is highly 
conserved among species. Furthermore, due to disulfide bond formation, 
cysteine residues are of structural significance (40, 46). Collectively, these 
oxidation events can rapidly alter protein-protein interaction, enzymatic activity, 
cellular localization, and protein stability. However, in order for redox signaling to 
have physiological significance, the oxidation of cysteine thiols to sulfenic acids 
or disulfide bonds must be a reversible process carried out by several types of 
antioxidants. On the other hand, pathological oxidation results from sustained 
levels of hydrogen peroxide, where sulfenic acids are further converted to sulfinic 
and sulfonic acids. These levels of oxidation are irreversible, and it typically 
renders the protein inactive or leads to unfolding and aggregation (Figure 2) (47, 
48).  
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Figure 2. Levels of cysteine oxidation. The thiol on a cysteine residue is 
reversibly oxidized to sulfenic acid, and can be reduced by several types of 
antioxidants. However, further oxidation to sulfinic and sulfonic acid are 
irreversible and typically render the protein inactive, as the chemical nature of the 
protein will change as a result of these oxidative modifications.  
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In an attempt the maintain protein homeostasis during oxidative stress, the cell 
will initiate the unfolded protein response (UPR) in both the endoplasmic 
reticulum (ER) and the mitochondria. Collectively, mitochondrial dysfunction and 
ER stress have been implicated in a variety of metabolic syndromes (49-53). The 
ER is the major site for protein folding, and through favorable thermodynamics 
and chaperone assisted folding, intramolecular disulfide bonds are formed, 
reduced and reformed in order to obtain the correct tertiary structure. Under 
heightened oxidative stress, this process is perturbed, and a variety of 
chaperones, kinases and transcription factors are activated to reestablish protein 
homeostasis. During the initial stages of protein unfolding HSP 70 chaperone, 
BiP (binding immunoglobulin protein) and the NF-κB pathway are activated to 
prevent apoptosis. However, if the capacity of BiP and other chaperones are 
overwhelmed, stress kinases, such as IRE1 and proapoptotic transcription 
factors, such as C/EBP homologous protein (CHOP) are activated in order to 
protect the rest of the tissue (54-56).  
 
Similar pathways are also activated in the mitochondria, as proteins will unfold as 
a result of mitochondrial derived ROS. Under these conditions, oxidative 
modifications change the chemistry of protein structure, and hydrophobic 
residues are exposed during the conformational changes that occur as a result of 
oxidation. As a counteractive mechanism, the mitochondria upregulates heat 
shock protein chaperones, such as HSP 60, to facilitate protein refolding. 
However, with sustained levels of ROS, proteases including Clp protease and 
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Lon protease are activated to prevent aggregation of these hydrophobic patches 
(43, 57). Finally, just like the ER unfolded protein response, the mitochondria will 
activate apoptotic pathways if homeostasis cannot be achieved. Importantly, one 
such consequence of the mitochondrial intrinsic apoptotic pathway is activation of 
the inflammasome, which is a central player of macrophage polarization 
described in this thesis (36, 42, 58).  
 
Due to this intimate relationship between cellular function and protein 
homeostasis, maintaining the cellular redox capacity is of the utmost important. 
Antioxidants are probably one of the most widely appreciated systems that 
reduce the level of ROS and prevent higher oxidation of cysteine residues (59-
61). These antioxidants include a diverse range of enzymes (including multiple 
isoforms), small peptides (i.e. glutathione), vitamins and other molecules. These 
factors may directly scavenge free radicals, as is the case with glutathione, or 
they can initiate upstream events that prevent the initial production of ROS. The 
uncoupling protein 2 (UCP2) performs the latter in mitochondrial derived ROS.  
 
UCP2 is a transmembrane protein that lowers the mitochondrial membrane 
potential by transporting 4-carbon molecules into the cytoplasm (62). Lowering 
the membrane potential facilitates efficient electron movement across the 
electron transport chain complexes, thereby reducing the chance of an electron 
reacting with oxygen (63). Lowered expression of UCP2 has demonstrated to 
have essential regulatory functions of pathogen elimination in macrophages. 
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However, in the context of obesity-related metabolic disease, increased 
expression of UCP2 is correlated with a lower risk of type-II diabetes and overall 
improved metabolic health (64, 65). These findings make UCP2 an attractive 
protein to study as a potential therapeutic in chronic inflammation by modulating 
redox homeostasis. Of particular importance, Xu et al. demonstrated the 
expression of UCP2 was negatively regulated by FABP4 in macrophages. This 
provides a critical link between FABP4 and redox signaling in the regulation of 
adipose tissue macrophage polarization. 
 
GOALS AND OBJECTIVES 
The link between obesity and metabolic health is strongly connected to both 
inflammation and oxidative stress events. This is supported by observations that 
immune cell populations differ in lean and obese adipose tissue as well as in 
obese metabolically healthy and unhealthy individuals. Furthermore, in several 
mouse studies, metabolic health was maintained during a high fat diet when 
inflammation was blunted (17, 25, 66-68). One explanation for these results is 
that inflammatory factors and ROS signal adipocytes to upregulate stress 
kinases. This in turn leads to insulin resistance and improper lipid storage (33, 
68, 69). However, in order to fully understand the disease progression associated 
with obesity, the pathways that are altered in a polarizing macrophage requires 
further study. This thesis is a culmination of work that has been conducted 
related to FABP4 and UCP2 expression in macrophages that has dramatic 
effects in regulating macrophage inflammatory and oxidative stress pathways. As 
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a result of the work described herein, the molecular mechanisms in which a 
macrophage maintains an anti-inflammatory characteristic, even under obese 
conditions, has been more clearly elucidated.  
 
The first objective in this thesis was to define the mechanism in which FABP4 
null macrophages exhibited an M2-like phenotype. As discussed in chapter two, 
it was determined to be largely due to the upregulation of the uncoupling protein 
2 (UCP2) in response to increased levels of palmitoleic acid. UCP2 expression 
reduced reactive oxygen species, inflammatory cytokines and endoplasmic 
reticulum stress and improved mitochondrial function. However, UCP2 
upregulation was not able to explain the increased beta-oxidation of FABP4 null 
macrophages. This phenotype was determined to be dependent on the induction 
of sirtuin 3 (SIRT3). Moreover, SIRT3 expression also demonstrated to play a 
role in blunting the expression of inflammatory cytokines and ROS production in 
addition to the effects of UCP2.  
 
Although these data helped elucidate the proteins responsible for reduced 
inflammation and oxidative stress, there were still mechanistic gaps as to how 
these pathways were altered. This led to the third objective in examining the role 
ROS plays in modifying cysteine residues through oxidation events. As shown in 
chapter 4, FABP4 null mice had enhanced antioxidant expression and 
concomitant reduced global cysteine oxidation, mitochondrial unfolded protein 
response and inflammasome activation. Another mechanism in which 
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macrophages alter their inflammatory phenotype is through changes in metabolic 
dynamics. In the final objective of this thesis, it was observed that the 
tricarboxylic acid (TCA) cycle was altered, leading to elevated levels of itaconate. 
These data indicate that ROS signaling and metabolic alterations are dependent 
on the expression of FABP4 in macrophages in determining the inflammatory 
fate of the cell.  
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SUMMARY  
Chronic inflammation in obese adipose tissue is linked to endoplasmic reticulum 
(ER) stress and systemic insulin resistance.  Targeted deletion of the murine 
adipocyte fatty acid binding protein (FABP4/aP2) uncouples obesity from 
inflammation, although the mechanism underlying this finding has remained 
enigmatic.  Herein we show that inhibition or deletion of FABP4/aP2 in 
macrophages results in increased intracellular free fatty acids and elevated 
expression of uncoupling protein 2 (UCP2) without concomitant increases in 
UCP1 or UCP3.  Silencing of UCP2 mRNA in FABP4/aP2 deficient macrophages 
negated the protective effect of FABP loss and increased ER stress in response 
to palmitate or lipopolysaccharide (LPS).  Pharmacologic inhibition of FABP4/aP2 
with the FABP inhibitor HTS01037 also up-regulated UCP2 and reduced 
expression of BiP, CHOP and XBP-1s.  Expression of native FABP4/aP2 (but not 
the non-fatty acid binding mutant, R126Q) into FABP4/aP2 null cells reduced 
UCP2 expression suggesting that the FABP-FFA equilibrium controls uncoupling 
protein 2 expression.  FABP4/aP2 deficient macrophages are resistant to LPS-
induced mitochondrial dysfunction, exhibit decreased mitochondrial protein 
carbonylation and UCP2-dependent reduction in intracellular reactive oxygen 
species. These data demonstrate that FABP4/aP2 directly regulates intracellular 
FFA levels and indirectly controls macrophage inflammation, and ER stress by 
regulating the expression of UCP2.   
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INTRODUCTION  
Obesity-linked metabolic disorders including insulin resistance, fatty liver 
disease, and coronary arterial disease share the common signature of chronic 
inflammation and endoplasmic reticulum (ER) stress (1, 2).  Macrophage and T 
cell infiltration and activation in adipose tissue plays a key role in affecting 
adipokine synthesis and secretion thereby regulating systemic insulin resistance 
(3).  Inflammatory cytokines increase oxidative stress and decrease the protein-
folding efficiency of the ER initiating a counter regulatory unfolded protein 
response (UPR) (4) involving pancreatic ER kinase (PERK), activating 
transcription factor-6 (ATF6), and inositol requiring enzyme 1 (IRE1).  Such 
concomitant activation leads to the downstream activation of response pathways 
and the induction of inflammatory signaling networks via JNK (c-Jun N-terminal 
kinase) and/or NF-κB (nuclear factor kappa B) (1).  
 
Lipid metabolism in macrophages has been shown to play an important role in 
triggering inflammation and ER stress (5, 6) and has led to the identification of 
critical proteins that regulate the obesity-metabolic disease axis.  For example, 
genetic ablation of the adipocyte fatty acid binding protein (FABP4, also known 
as aP2) in macrophages alone is sufficient to protect the mice from development 
of atherosclerosis and dyslipidemia (7).  FABP4/aP2 is a cytoplasmic fatty acid 
carrier protein that mediates intracellular fatty acid trafficking and a number of 
hypotheses have been proposed for why the loss of FABP4/aP2 results in 
metabolic improvement (6). Moreover, small molecules that target FABP4/aP2 
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have been developed as potential therapeutics (8). However, conflicting reports 
exist concerning the effectiveness of these inhibitors using cell-based and animal 
models (9).  FABP4/aP2 deficient macrophages exhibit suppressed inflammatory 
signaling, attenuated activation of the NF-κB pathway and decreased ER stress 
(6, 10).  Consistent with a role for FABP4/aP2 as a key determinant in obesity-
linked inflammation, genetic variation in the human FABP4/aP2 promoter that 
leads to decreased expression of the protein in adipose tissue is associated with 
lower serum triglyceride levels, reduced coronary disease and type 2 diabetes 
(11). The biochemical processes underlying the effects of FABP4/aP2 deficiency 
on macrophage lipid metabolism and ER stress and inflammatory pathways are 
not understood, but may be linked to the accumulation of intracellular 
unsaturated fatty acids, particularly palmitoleic acid (6, 10).   
 
The investigation herein describes the novel finding that UCP2 is up-regulated 
selectively in macrophages from FABP4/aP2 null mice and that increased 
expression of UCP2 plays an important and essential role in alleviating ER stress 
and decreasing inflammation (12, 13).  Unlike its structural homolog UCP1 that is 
highly expressed in brown fat, UCP2 is more broadly expressed in various 
tissues and cells, functions as a sensor of mitochondrial oxidative stress and is 
generally considered to be cytoprotective (14).  Moreover, unsaturated fatty acids 
increase UCP2 expression in macrophage cells suggesting that the FABP – fatty 
acid equilibrium is central to mediating metabolic homeostasis.   
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MATERIALS AND METHODS 
Cell lines. FABP4/aP2 knockout and wild type macrophage cells were 
maintained in RPMI 1640 (Invitrogen) with 5% fetal bovine serum (FBS).  
Raw264.7 macrophages as well as UCP2 knockdown Raw264.7 macrophages 
were maintained in DMEM (Invitrogen) with 10% FBS.  Peritoneal macrophages 
were isolated from C57Bl/6J animals. 1-2 X106 cells were plated and incubated 
overnight (15).  
Intracellular fatty acid analysis.  Monolayers of cells were washed with 
phosphate-buffered saline and harvested into 2 mL of 100 mM sodium acetate 
(pH 3.9).  Lipids were extracted into hexane: isopropanol: H2O (3:2:2) and 
centrifuged at 3000 rpm for 10 minutes to achieve phase separation.  The 
aqueous phase was dried under nitrogen and lipids solubilized in 1 mL 
chloroform.  Samples were loaded onto equilibrated HF Bond Elut NH2 column 
(Agilent Technology), washed with chloroform: isopropanol (2:1) to remove 
neutral lipids and fatty acids eluted with 2% acetic acid in diethyl ether.  The fatty 
acid eluate was dried and resolubilized in isopropanol for measurement of fatty 
acid abundance (NEFA kit, Wako) or submitted to the Metabolomics Resources 
Core of the Mayo Clinic (Rochester MN) for fatty acid composition analysis.  The 
fatty acid composition analysis was carried out by LC-MS with C17:0 spiked in 
each sample as an internal standard.   
 
Isolation of stromal vascular cells. Epididymal fat pads were dissected from 
wild type C57Bl/6J and FABP4/aP2 KO mice (n=6) maintained on high fat diet for 
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12 weeks (16).  Briefly, fat pads were minced and digested with Type I 
collagenase in Krebs-Ringers-Hepes buffer supplemented with 10 mg/ml BSA.  
After incubation at 37° C for 1 hour, the mixture was filtered with cell strainer 
(100µm Nylon, FALCON) to remove undigested tissues. The stromal vascular 
fraction was collected by centrifugation at 500 g for 10 minutes.  The stromal 
vascular fraction was washed and TRIzol reagent used for RNA isolation.  All 
experimental procedures using animals were reviewed and approved by the 
University of Minnesota Institutional Animal Care and Use Committee.   
 
shRNA knockdown of UCP2 in macrophages. Raw264.7 and FABP4/aP2 KO 
macrophages were transduced with shRNA lentivirus as described previously 
(17).  GFP scrambled and Ucp2 targeting sequences were obtained from Open 
Biosystems. Ucp2 (NM_011671) targeting sequence (UCP2 kd): 
5’CCGGTCTCCCAATGTTGCCCGTAATCTCGAGATTACGGGCAA 
CATTGGGAGATTTTTG-3’; alternative UCP2 targeting sequence (UCP2-2 kd): 
CCGGCCCA 
GCCTACAGATGTGGTAACTCGAGTTACCACATCTGTAGGCTGGGTTTTTG-3’; 
the scrambled sequence: 5’-AACGTACGCGGAATACTTCGA-3’.   
 
Expression analysis by Quantitative Real time PCR (qRT-PCR). Total RNA 
was isolated using TRIzol reagent (Invitrogen), and reverse transcribed to cDNA 
using iScript according to the manufacturer’s protocol (Bio-Rad).  qRT-PCR 
amplification was performed on a Bio-Rad CFX 96 Real-Time System using 
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SYBR Green Supermix (Bio-Rad). Transcription factor II E (TFIIE) was used as 
an internal control to normalize expression unless specified otherwise. Primer 
sequences are provided in Table 1.  
 
Reverse transcription PCR analysis (RT-PCR). RT-PCR was used to identify 
UCP1, UCP2, and UCP3 expression in macrophages. Primers for UCP1 forward: 
GCCAGGCTTCCAGTACATTA, UCP1 reverse: 
TGGTACGCTTGGGTACTGTCC; UCP2 forward: 
CCAGAGCACTGTCGAAGCCT, UCP2 reverse: 
GCAGCCATTAGGGCTCTTTTG; UCP3 forward: AGAACCCAGGGGCTCAGAG, 
UCP3 reverse: AAAACGGAGATTCCCGCAGTA. 
 
Cellular respiratory Assay. Macrophage respiratory assay was performed on a 
XF24 extracellular flux analyzer (Seahorse Biosciences) (18).  Macrophages 
were plated on V7 microplates at a density of 300,000 cells per plate, incubated 
overnight, and then cells were treated either with vehicle or lipopolysaccharide 
(LPS) (100ng/ml) for 6 hours. During the assay, cells were exposed to 
compounds in the following order: 2 µM oligomycin, 0.4 µM FCCP, and 4 µM 
antimycin A.  
 
Hydrogen Peroxide (H2O2) assay. H2O2 quantification was determined using 
Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Invitrogen) according to 
the manufacturer’s protocol with modification.  Briefly, cells were scraped into 
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phosphate buffer (pH7.4) and inactivated at 95°C for 10 minutes. After spin down 
of cell debris, 50 µL of supernatant were loaded with 50 µL working solution.  
Following 30 minutes incubation, fluorescence was measured using a microplate 
reader with excitation at 540 nm and emission at 590 nm.  
 
Membrane potential measurement. Mitochondrial proton motive force was 
measured by tetramethylrhodamine, methyl ester (TMRM) staining (Invitrogen). 
Briefly, cells were washed with PBS, and incubated in 1 mL of KRH buffer 
(pH7.4) with 20 nM final concentration of TMRM for 30 minutes. Then cells are 
washed with PBS and harvested into 300 µL KRH buffer. 150 µL of each sample 
was load into 96-well plate and fluorescence was measured using microplate 
reader with excitation at 531 nm and emission at 572 nm.  
 
Mitochondrial isolation. Cells were scraped into isolation buffer (20 mM Tris 
(pH 7.4), 220 mM mannitol, 70 mM sucrose, 1 mM EDTA, 0.1 mM EGTA) 
supplemented with protease inhibitors and lysed with 20 strokes of a Dounce 
homogenizer.  Homogenates were centrifuged at 700g for 10 minutes to remove 
nuclei and unbroken cells.  Mitochondria were pelleted by centrifugation at 
12,000g for 15 minutes. 
 
Immunoblotting. Cells were lysed in RIPA buffer supplemented with protease 
inhibitors. Equal amounts of protein were separated by SDS-PAGE and 
transferred to PVDF membrane. After blocking, membranes were incubated with 
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primary antibody overnight at 4° C.  Membranes were washed and incubated 
with secondary antibody conjugated to LI-COR IR Dye for 1 hour and visualized 
using LI-COR Odyssey infrared imaging (LI-COR biotechnologies).  The 
antibodies used were anti-UCP2 (Santa Cruz Biotechnology, C-20), anti-HNE 
(Millipore), anti-DDIT3 (anti-CHOP) (Abcam), anti-GPR78 (Bip) (Santa Cruz 
Biotechnology, H-129), anti-Cox2 & anti-iNOS (BD Transduction Laboratories), 
anti-β-Actin (Sigma Aldrich) and anti-ATP synthase-α subunit (MitoSciences).   
 
Cytokine TNFα measurement. Secreted TNFα in medium (8hr) was measured 
with Mouse TNF ELISA Set from BD Biosciences according to the 
manufacturer’s instruction. 
 
Fatty acid oxidation assay. Fatty acid oxidation was carried out as described by 
Wiczer and Bernlohr (19).  Briefly, cells were incubated for 1 hour at 37°C in 
Krebs-Ringers-Hepes buffer (pH7.4), containing 5.4 mM glucose and 400 µM 
[14C] palmitic acid bound to 100 µM fatty acid free BSA.  Cells were scraped from 
the plates and transferred with media into 20 mL glass reaction vials containing a 
center reaction tube filled with 400 µL 1M sodium hydroxide.  70% perchloric acid 
was added to the media (final concentration of 7%), incubated for 1 hour with 
shaking at 80 rpm. After incubation, the content of the center tube was 
transferred into 10 mL liquid scintillation fluid and the 14CO2 determined by liquid 
scintillation counting. 
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Statistical analysis. All data in the paper are expressed as standard deviation (± 
SD). Statistical significance was determined using an unpaired, two-tailed 
Student t test. 
 
RESULTS 
Loss or inhibition of FABP4/aP2 in macrophages leads to increased UCP2 
expression. Previous reports have demonstrated that the intracellular fatty acid 
pool in FABP4/aP2 deficient macrophages and adipocytes is increased and has 
an altered composition (6, 20).  Work in other systems, particularly in the liver, 
has shown that the expression of UCP2 mRNA and protein is increased with 
obesity, regulated by fatty acids and that lipid overload leads to increased 
expression of UCP2 as part of a counter regulatory cycle (14, 21).  Since FABPs 
establish an intracellular equilibrium between bound and free fatty acids, we 
hypothesized that loss of FABP4/aP2 would result in increased availability of lipid 
and up-regulation of UCP2.  To test this hypothesis, we evaluated the expression 
of uncoupling proteins using qRT-PCR and determined that UCP2 mRNA is 
increased approximately 60% in FABP4/aP2 deficient SVF cells compared to that 
of wild type mice (Fig. 1A).  Similarly, UCP2 mRNA levels were increased ~ 2-
fold in cell lines derived from FABP4/aP2 deficient mice (referred to as AKO 
macrophages) compared to control cells (Fig. 1B).  The phenotype of 
FABP4/aP2 deficiency in macrophages can be mimicked by treatment of cultured 
macrophages with a previously identified and characterized chemical inhibitor of 
FABPs, HTS01037 (8). Treatment of Raw264.7 macrophages with HTS01037 
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also significantly increases UCP2 mRNA level (Fig. 1C). To further confirm that 
the up-regulation of UCP2 is responsive to FABP4/aP2 deficiency, AFABP/aP2-/- 
macrophages were reconstituted with either a wild type FABP4/aP2 or a non-
fatty acid binding mutant of AFABP/aP2 (R126Q) (22) to a level comparable to 
that of FABP4/aP2 in wild type macrophages (results not shown). Re-expression 
of wild type FABP4/aP2, but not the R126Q mutant, reduces UCP2 mRNA to a 
level comparable to that in wild type macrophages (Fig. 1B) implying that the 
intracellular FFA-FABP equilibrium is a major control element for UCP2 
expression. Analysis of UCP2 protein levels in FABP4/aP2 deficient 
macrophages show that UCP2 is significantly increased compared to that of wild 
type (Fig. 1D). Moreover, the treatment of Raw264.7 macrophages with the 
FABP inhibitor HTS01037 also increases UCP2 protein level (Fig. 1E).  
Furthermore, the increased expression of uncoupling protein was specific for 
UCP2 as there was no evidence for any expression of UCP1 or UCP3 (Fig. 1F).  
These results in sum indicate that FABP4/aP2-FFA equilibrium controls the 
expression of the UCP2. 
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Figure 1. Loss of FABP4/aP2 increases UCP2 expression.  (A) UCP2 mRNA 
level normalized to macrophage F4/80 in the stromal vascular fraction of 
epididymal adipose tissue obtained from high fat diet fed wild type (WT) and 
AFABP/aP2-/- (AKO) mice. (B) UCP2 mRNA level in wild type, AKO, AKO+native 
(AFABP/aP2-/- macrophages reconstituted with WT AFABP/aP2), AKO+R126Q 
(AFABP/aP2-/- macrophages reconstituted with a non-fatty acid binding mutant of 
AFABP/aP2). (C) UCP2 mRNA level in Raw264.7 macrophages treated with 30 
µM HTS01037 for 24 hours.  (D) UCP2 protein expression in AKO and WT 
macrophage mitochondrial fraction determined by western blot. (E) UCP2 
expression in Raw264.7 macrophages treated with 30 µM HTS01037 determined 
by western blot. (F) RT-PCR amplification of UCP1, 2 and 3 from wild type (WT) 
and FABP4/aP2-/- (AKO) macrophages. Amplification of UCP1 from brown fat (B-
fat) was used as positive control for UCP1 expression, while UCP3 expression 
control was amplified from a heart cDNA sample. (* p<0.05, ** p<0.01) 
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Unsaturated fatty acids induce UCP2 expression in macrophages via 
PPARγ. Previous reports have shown that in multiple systems UCP2 expression 
can be induced by unsaturated fatty acids (14, 23-25).  Moreover, FABPs are 
identified as lipid chaperones involved in establishment of the bound vs. free FFA 
equilibrium (16, 26).  Consistent with previous work, intracellular free fatty acids 
in FABP4/aP2-/- macrophages were increased ~70% compared to that of wild 
type (Fig. 2A) (6).  Moreover, fatty acid composition analysis revealed that 
monounsaturated fatty acid levels such as oleic acid (18:1), palmitoleic acid (16:1 
cis) and palmitelaidic acid (16:1 trans) were selectively elevated in FABP4/aP2-/- 
macrophages (Fig. 2B). To test which molecular species of fatty acid could 
induce UCP2 expression in macrophages, Raw264.7 cells were treated for 24 
hours with different fatty acids (4:1 FFA/bovine serum albumin) and the 
expression of UCP2 evaluated.  The results demonstrate that polyunsaturated 
fatty acids, including DHA (22:6), EPA (20:5), linoleate (18:2) and the 
monounsaturated fatty acids oleate (18:1) and palmitoleate (16:1) can each 
induce UCP2 expression in macrophages, while the saturated fatty acid palmitate 
(16:0) was unable to elicit any response (Fig. 2C).  Unsaturated fatty acids have 
been shown to act as ligands of a family of transcription factors - peroxisomal 
proliferator-activated receptors (PPARs) which are involved in regulating the 
expression of a cohort of genes involved in lipid metabolism (27).  PPARγ is the 
major form of PPARs expressed in macrophages and suppresses the expression 
of a large set of inflammatory genes (28).  qRT-PCR analysis shows that both 
PPARγ and its target genes such as liver X receptor alpha (LxRα), cluster of 
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differentiation 36 (CD36), arginase and stearoyl-CoA desaturase-1 (SCD1) were 
up-regulated in FABP4/aP2-/- macrophages compared to that of wild type 
macrophages. On the contrary, the expression of the proinflammatory gene, 
inducible nitric oxide synthase (iNOS), is down regulated in FABP4/aP2-/- 
macrophages (Fig. 2D). In addition, treatment of wild type peritoneal 
macrophages with the FABP inhibitor HTS01037 shows similar results (Fig. 2E). 
In order to determine the role of PPARγ in macrophage UCP2 expression, 
Raw264.7 cells were treated with the PPARγ agonist troglitazone.  Troglitazone 
treatment increased the expression of UCP2 in macrophages, as well as LXRa 
(Fig. 2F).  On the other hand, treatment of FABP4/aP2-/- macrophages with 
PPARγ antagonist GW9662 reduced UCP2 expression to a level comparable to 
that of wild type (Fig. 2G).  
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Figure 2. Unsaturated fatty acids induce UCP2 expression via PPARγ.  (A) 
Intracellular free fatty acids measured in WT (wild type) and AKO (FABP4/aP2-/-) 
macrophages. (B) Fatty acid composition in WT and AKO macrophages. (C) 
UCP2 mRNA level in Raw264.7 macrophages treated with 300 µM 
docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), linoleate, oleate, 
palmitoleate, or palmitate. Fatty acids were added in complex to bovine serum 
album at a molar ratio of 4:1.  (D) mRNA levels of PPARγ, liver X receptor alpha 
(LxRα), cluster of differentiation 36 (CD36), arginase, stearoyl-CoA desaturase 1 
(SCD1) and inducible nitric oxide (iNOS) in WT and AKO peritoneal 
macrophages. (E) PPARγ, LxRα, CD36, Arginase, SCD1 and iNOS mRNA level 
in 10 µM HTS01037 treated WT peritoneal macrophages. (F) mRNA level of 
LxRα and UCP2 in Raw264.7 macrophages treated with 5 µM troglitazone for 24 
hours. (G) mRNA level of UCP2 in WT and AKO macrophages treated with 5 µM 
GW9662 for 24 hours. (* p<0.05, ** p<0.01) 
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UCP2 up-regulation negates palmitate-induced ER stress in FABP4/aP2 
deficient macrophages. The alleviation of lipid-induced macrophage ER stress 
can be accomplished either by knocking out FABP4/aP2 genetically or inhibiting 
the FABP-fatty acid interaction with small molecule inhibitors (6).  In addition, the 
reduction in macrophage ER stress has been shown to offer protection against 
atherosclerosis (29).  We therefore evaluated the role of UCP2 up-regulation in 
FABP4/aP2-/- macrophages as mediating reduced ER stress in palmitate-treated 
macrophages by silencing UCP2 in AKO and Raw264.7 macrophages (Fig. 3A 
and B). Spliced x-box binding protein 1 (XBP-1s) (30, 31) was markedly down-
regulated in Raw264.7 cells treated with HTS01037, while the level of the 
unspliced form was increased, suggesting loss of FABP4/aP2 protects 
macrophages from ER stress (Fig. 4A). Treatment of UCP2 knockdown and 
control cells with HTS01037 shows that UCP2 silenced macrophages have a 
basal increase of XBP-1s and a blunted response to HTS01037 (Fig. 4B).   
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Figure 3. Knock down of UCP2 in FABP4/aP2 deficient and Raw 264.7 
macrophages.  
(A) UCP2 mRNA levels in wild type (WT), AKO, and AKO-UCP2 kd (UCP2 
knockdown AKO macrophages). (B) UCP2 mRNA levels in control cells, UCP2 
kd and UCP2-2 kd (alternatively silenced UCP2 knock down cells) Raw264 
macrophages.  (* p<0.05, ** p<0.01) 
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Lipid loading, especially palmitate treatment, has been shown to induce 
expression of proteins involved in ER stress response, such as C/EBP 
homologous protein (CHOP) and immunoglobulin heavy chain binding protein 
(Bip) (6).  To assess the role of UCP2 induction in regulating ER stress response 
to palmitate, UCP2 knockdown and control cells were pretreated with HTS01037 
or vehicle and palmitate-induced ER stress was evaluated.  Expression of CHOP 
and Bip with palmitate treatment was markedly reduced in response to 
HTS01037 treatment in macrophages and this protection was negated in UCP2 
knockdown macrophages (Fig. 4C-E).  In order to further determine the role of 
UCP2 in inhibiting the ER stress response, UCP2 was knocked down in 
FABP4/aP2 deficient macrophages (AKO-UCP2 kd) and palmitate-induced ER 
stress evaluated.  Importantly, palmitate treatment of macrophages showed 
increased expression of CHOP and Bip in wild type and AKO-UCP2 kd 
macrophages, as compared to FABP4/aP2-/- (AKO) macrophages (Fig. 4F and 
G).  Taken together, these results strongly indicate that UCP2 expression in 
FABP4/aP2 deficient macrophages plays an important role in mediating the 
reduced lipid-induced ER stress.  
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Figure 4. UCP2 up-regulation mediates decreased ER stress in FABP4/aP2 
deficient macrophages.  
(A) XBP-1s and XBP-1u mRNA levels in Raw264.7 macrophages treated with 30 
µM HTS01037. (B) XBP-1s mRNA levels in UCP2 knockdown and control 
macrophage cell lines treated with 30 µM HTS01037 for 24 hours. (C-D) CHOP 
and (E) Bip abundance determined by western blot in UCP2 knockdown and 
control cells pretreated with vehicle or HTS01037 (30µM) for 3 hours and treated 
with 500 µM palmitate for 16 hours. (F) CHOP abundance determined by western 
blot in WT, AKO and AKO-UCP2 kd (UCP2 knockdown AKO macrophages) cells 
treated with 300 µM palmitate for 24 hours. (G) Bip abundance determined by 
western blot in WT, AKO and AKO-UCP2 kd cells treated with 500µM palmitate 
for 12 hours. (* p<0.05, ** p<0.01) 
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UCP2 mediates the decreased inflammatory signaling in FABP4/aP2 
deficient macrophages. FABP4/aP2-/- macrophages have reduced expression 
of inflammatory proteins such as cyclooxygenase-2 (Cox2) and iNOS (7, 10). In 
order to determine if UCP2 is involved in the suppression of inflammatory 
signaling in FABP4/aP2 knockout macrophages, wild type and FABP4/aP2-/- 
macrophages were treated with lipopolysaccharide (LPS) in the presence or 
absence of genipin, an UCP2 inhibitor (32) and the inflammatory response was 
profiled.  Consistent with previous studies, LPS-induced Cox2 expression and 
TNF-α secretion were significantly lower in FABP4/aP2-/- macrophages (Fig. 5A 
and B).  Moreover, LPS and genipin co-treatment of FABP4/aP2-/- macrophages 
significantly increased Cox2 expression and TNF-α secretion in FABP4/aP2-/- 
macrophages compared to that of LPS treatment alone (Fig. 5A and B) 
suggesting that increased UCP2 expression may attenuate inflammatory 
responsiveness.  To further confirm UCP2’s role in suppressing inflammatory 
signaling, control cells and UCP2 knockdown Raw264.7 macrophages were 
pretreated with HTS01037 and stimulated with LPS or LPS+INF-γ (interferon 
gamma).  HTS01037 treatment significantly reduced LPS induced Cox2 and LPS 
plus IFN-γ induced iNOS expression in control cells (Fig. 5C-E).  However, the 
effect of HTS01037 was significantly reduced, if not totally abolished, in UCP2 
knockdown macrophages (Fig. 5C-E).  Taken together, these data indicate that 
UCP2 plays an important role in mediating the reduced inflammation in 
FABP4/aP2 deficient macrophages and that the key determinant of metabolic 
improvement in FABP deficient mice is up-regulation of UCP2.   
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Figure 5  
UCP2 up-regulation mediates the decreased inflammation in FABP4/aP2 
deficient macrophages.  (A) Cyclooxygenae 2 (Cox2) abundance measured by 
western blot in WT and AKO macrophages co-treated with or without LPS (100 
ng/ml) ± genipin (40 µM) for 18 hours. (B) Secreted TNFα in cell culture medium 
determined by ELISA in WT and AKO macrophages co-treated with or without 
LPS (100 ng/ml) ± genipin (40 µM) for 8 hours. (C) Cox2 abundance determined 
by western blot in UCP2 knockdown and control macrophages pretreated with 
vehicle or HTS01037 (30 µM) for 3 hours and then treated with LPS (100 ng/ml) 
for 12 hours. (D-E) iNOS abundance determined by western blot in UCP2 
knockdown and control macrophages pretreated with vehicle or HTS01037 
(30µM) for 3 hours and then treated with LPS (100 ng/ml) +IFN-γ (10U) for 12 
hours (UCP2 kd) and 4 hours (UCP2-2 kd) macrophages (* p<0.05, ** p<0.01) 
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UCP2 decreases the hydrogen peroxide level and oxidative stress in 
FABP4/aP2 deficient macrophages. A well-defined role for UCP2 is 
suppression of reactive oxygen species (ROS) production (13, 14). In order to 
determine the effect of FABP4/aP2 loss on ROS level in macrophages, the 
intracellular hydrogen peroxide levels in both FABP4/aP2-/- and wild type 
macrophages were determined.  Figure 6A shows that FABP4/aP2-/- 
macrophages have a significantly lower level of intracellular hydrogen peroxide.  
Moreover, treatment of control and FABP4/aP2-/- macrophages with genipin to 
inhibit UCP2 attenuated the decreased ROS levels in FABP deficient cells but 
had little effect on control macrophages (Fig. 6B).  Interestingly, HTS01037 
treatment of Raw264.7 macrophages, which mimics the knockdown of 
FABP4/aP2, also led to decreased intracellular hydrogen peroxide (Fig. 6C). 
Moreover, HTS01037 treatment of UCP2 knockdown cells was not able to 
reduce the intracellular hydrogen peroxide level (Fig. 6D) suggesting the effect of 
HTS01037 treatment on hydrogen peroxide level is likely to be mediated by 
UCP2 expression as well.  Taken together, the results indicate that genetic loss 
or chemical inhibition of FABP4/aP2 leads to the reduced level of intracellular 
hydrogen peroxide in an UCP2-dependent manner.  
 
Oxidative stress is a key contributor to mitochondrial dysfunction and apoptosis 
(33, 34). Consistent with decreased hydrogen peroxide that is indicative of 
reduced oxidative stress, most of the antioxidants, if not all, are decreased in 
FABP4/aP2 deficient macrophages (Fig. 6E). Surprisingly, silencing of UCP2 
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also leads to a decrease in the mRNA expression for several antioxidant 
enzymes (Fig. 6E and F).  One of the effects of oxidative stress is protein 
carbonylation, the covalent modification of proteins with reactive lipid aldehydes 
that is linked to mitochondrial dysfunction (35).  Utilizing an antibody directed to 
carbonylated proteins, and consistent with reduced ROS levels, FABP4/aP2-/- 
macrophages exhibit reduced protein carbonylation (Fig. 6G). 
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Figure 6. UCP2 up-regulation decreases intracellular hydrogen peroxide in 
FABP4/aP2 deficient macrophages.  Intracellular hydrogen peroxide level 
measured by Amplex Red Assay in (A) WT and AKO macrophages, (B) WT and 
AKO macrophages treated with vehicle or genipin (50 µM) for 6 hours, (C) 
Raw264.7 macrophages treated with HTS01037 (30 µM) for 24 hr and  (D) UCP2 
knockdown and control cells treated with HTS01037 (30 µM) for 6 hours. 
Expression of antioxidant gene mRNA levels in (E) WT, AKO, AKO-UCP2 kd 
cells and (F) UCP2 knockdown and control cells.  (G) Protein carbonylation 
measured by western blot with anti-HNE antibody in WT and AKO mitochondrial 
protein. (* p<0.05, ** p<0.01) 
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FABP4/aP2-/- macrophages have higher mitochondrial respiration capacity. 
Reduced carbonylation is predictive of improved mitochondrial function and to 
test this hypothesis, cellular respiration was evaluated both at basal level and in 
response to a LPS challenge.  As shown in Figure 7, FABP4/aP2-/- macrophages 
exhibited a lower level of basal respiration, and ATP turnover, but a significantly 
higher level of maximum respiration. Upon LPS treatment, FABP4/aP2-/- 
macrophages have a significant increase of basal respiration and ATP turnover, 
while wild type macrophages lose the maximum respiration capacity (Fig. 7B-D). 
However, no difference of coupling efficiency and proton leak between the two 
cell lines or treatment was observed (Fig. 7E and F).  
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Figure 7. Cellular respiration of FABP4/aP2 deficient and wild type 
macrophages. (A-F) Oxygen consumption rates in WT and AKO macrophages 
treated with or without LPS (100 ng/ml) for 4 hours (oligomycin, 2 µM; FCCP, 0.4 
µM; antimycin, 4 µM). (* p<0.05, ** p<0.01) 
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UCP2 mediates decreased basal respiration and lactate production of 
FABP4/aP2-/-macrophages but not the increased fatty acid oxidation. 
Consistent with a role of UCP2 in control of basal respiration, silencing of UCP2 
in FABP4/aP2-/- macrophages increased basal, but not maximal respiration 
compared to control cells (Fig. 8A). Additionally, fatty acid oxidation was 
increased in macrophages lacking FABP4/aP2 (Fig. 8B).  However, no difference 
of fatty acid oxidation was observed in UCP2 knock down FABP/aP2-/- or 
Raw264.7 macrophages (Fig. 8B and C) suggesting an UCP2-independent 
process.  FABP4/aP2-/- macrophage cell culture medium had reduced lactate 
compared to wild type macrophages (Fig. 8D).  This is consistent with the lower 
basal respiration of FABP4/aP2-/- macrophages (Fig. 7B). In support of the role of 
UCP2 mediating the decreased lactate production in FABP4/aP2-/- macrophages, 
the lactate level was increased about 70% in the cell culture medium of UCP2 
knock down FABP4/aP2-/- cells and UCP2 knockdown Raw264.7 cells compared 
with control macrophages (Fig. 8D and E). 
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Figure 8. Metabolic impact of UCP2 silencing on macrophages. 
(A) Oxygen consumption rate in FABP4/aP2 deficient and AKO-UCP2 kd 
macrophages. (B) β-oxidation measured in WT, AKO, AKO-UCP2 kd cells. (C) β-
oxidation measured in UCP2 kd cells and control cells. (D) Cell culture media 
lactate level measured in WT, AKO, AKO-UCP2 kd cells. (E) Cell culture media 
lactate level measured in UCP2 knockdown and control cells. (* p<0.05, ** 
p<0.01) 
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DISCUSSION 
Chronic activation of ER stress and inflammation in macrophages contributes to 
the pathogenesis of various metabolic disarrangements such as atherosclerosis 
and type 2 diabetes (4, 29). The stressors that can lead to macrophage ER 
stress and inflammation include oxidative stress, high level of intracellular 
cholesterol and saturated fatty acids (29). Prolonged elevation of macrophage 
ER stress and inflammation has been proposed to contribute to macrophage 
apoptosis and lead to plaque necrosis and rupture (2, 36).  Therefore, 
understanding of biological processes involved in counteracting macrophage ER 
stress and inflammation is crucial for development of specific strategies to 
improve metabolic poise.  Interestingly, FABP4/aP2 has been shown to play an 
important role in mediating both ER stress and inflammation in macrophages (6, 
37). Genetic ablation or chemical inhibition of FABP4/aP2 alleviates macrophage 
inflammation and ER stress (6, 8, 10).  The increase of monounsaturated fatty 
acids, PPARγ, and LxRα activity have all been suggested as mediating the anti-
inflammatory and anti-ER stress effects of FABP4/aP2 deficiency (6, 10).  
However, the molecular relationship of FABP deficiency to inflammation and ER 
stress outcome is still unclear.  Increased expression of UCP2 in FABP4/aP2-/- 
macrophages provides a mechanistic basis for the anti-inflammatory, anti-ER 
stress outcomes. Studies in a number of systems have implicated UCP2 as a 
major control element in macrophage ER stress, inflammation and diet induced 
atherosclerosis (38-40).  Interestingly, a UCP2 promoter region -866G>A 
polymorphism which decreases UCP2 expression has been associated with 
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increased risk of obesity, decreased insulin level and type 2 diabetes (14).  
Moreover, type 2 diabetes patients bearing the G allele have a higher 
inflammatory status (41).  In a second study, a UCP2 -86G>A polymorphism is 
associated with multiple chronic inflammatory diseases, including Crohn’s 
disease, ulcerative colitis, and psoriasis (42).   
 
It has been proposed that unsaturated fatty acids (or their metabolites) are 
potential ligands for LxRα and PPARγ (27).  Fatty acids and the expression of 
LxRα and PPARγ are increased in FABP4/aP2 deficient macrophages and have 
all been previously shown to up-regulate UCP2 expression (14).  Interestingly, a 
previous study by Erbay et al. showed that the unsaturated fatty acid pool is 
increased in FABP4/aP2-/- macrophages (6).  Results herein show that 
monounsaturated fatty acids are increased in FABP4/aP2-/- macrophages, and 
unsaturated, but not saturated, fatty acids induce UCP2 expression in 
macrophages, consistent with a report on fatty acid induction of UCP2 in liver 
cells (43).  Moreover, given the increase in the intracellular free fatty acid pool in 
FABP4/aP2-/- macrophages, it is very likely they directly or indirectly activate 
PPARγ, thereby inducing UCP2 expression. However, this does not exclude the 
possibility that fatty acids may also directly regulate UCP2 activity.   
 
Paradoxically, despite the existence of the other FABP in macrophages 
(FABP5/mal1), the deficiency of FABP4 leads to an anti-inflammatory and anti-
atherosclerotic phenotype (7).  One explanation is that FABP4 has a higher 
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affinity for unsaturated fatty acids compared to FABP5 (44).  Therefore, the loss 
of FABP4 will affect the pool of available free unsaturated fatty acids, especially 
monounsaturated fatty acids.  An additional possibility is the pools of fatty acids 
bound to FABP4 are distinct from those bound to FABP5, such that loss of 
FABP4 could exhibit a unique phenotype.  Experiments to test these hypotheses 
are currently underway. 
 
The reduced ER stress and inflammation demonstrated in both FABP4/aP2 
deficient and FABP4/aP2 inhibited macrophages was markedly abolished or 
compromised by knockdown or inhibition of UCP2.  This observation places 
UCP2 as a modulator between the FABP-FFA equilibrium and ER stress and 
inflammation, which is a role for UCP2 that has previously not been appreciated.  
It is noteworthy that the findings do not rule out contributions from other parallel 
pathways that reduce ER stress and inflammation.  However, the results imply 
that the UCP2 mediated pathway is likely the major determinant of the 
FABP4/aP2 deficient macrophage phenotype since UCP2 knockdown or 
inhibition greatly compromised the protection from loss of FABP4/aP2 function. 
 
The prominent and well-defined role of UCP2 is to suppress ROS (13). The data 
herein show that FABP4/aP2-/- macrophages have a lower level of intracellular 
hydrogen peroxide that is dependent on UCP2 expression as evidenced by 
restoration via genipin inhibition of UCP2.  Hydrogen peroxide has been shown 
to directly oxidize the side chains of several amino acids, particularly cysteine, 
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thereby affecting the cellular redoxome.  Alternatively, if not detoxified by 
antioxidants such as catalase, peroxiredoxin, or glutathione peroxidase, 
hydrogen peroxide could react with iron to form hydroxyl radicals and oxidize 
lipids.  4-hydroxynonenal (4-HNE) and 4-oxononenal (4-ONE) are the two most 
well studied lipid peroxidation products and have been shown to covalently 
modify proteins, a process termed as protein carbonylation. This frequently leads 
to loss or alteration of protein activity and mitochondrial dysfunction (35, 45). 
Interestingly, a decreased level of mitochondrial protein carbonylation was 
observed in FABP4/aP2-/- macrophages consistent with improved mitochondrial 
function (35).  The results in Figure 7 demonstrating that FABP4/aP2-/- 
macrophages were protected from LPS-induced loss of mitochondrial respiration 
capacity support this concept.  Interestingly, it has been shown that LPS induced 
mitochondrial dysfunction mainly relies on the increased ROS production and 
suppression of ROS not only protects cells from LPS induced mitochondrial 
dysfunction but also greatly attenuates LPS induced inflammatory responses (46, 
47).  Further work is still required to determine if the decreased hydrogen 
peroxide level in FABP4/aP2-/- macrophages is responsible for the protection 
from LPS induced mitochondrial dysfunction.   
 
Both hydrogen peroxide and oxidized lipids have also been shown to activate ER 
stress and inflammatory pathways (48, 49).  It is tempting to speculate that the 
UCP2 suppression of ROS in FABP4/aP2-/- macrophages broadly impacts not 
only mitochondrial function but also endoplasmic reticulum function and 
	 61				
inflammatory pathway activity (Fig. 9). Interestingly, knockdown of UCP2 in 
macrophages increases lactate production. The increased lactate production 
indicates increased energy production through glycolysis, a common indicator of 
electron transport chain dysfunction (50).  Additionally, this may also explain 
UCP2 dependency of the lower basal respiration of FABP4/aP2 deficient 
macrophages.  As a suppressor of ROS production, higher UCP2 expression in 
FABP4/aP2-/- macrophages leads to lower cellular oxidative stress.  Since 
oxidative stress drives the up-regulation of antioxidants, it is reasonable that 
most genes linked to antioxidant biology are expressed at lower levels in 
FABP4/aP2-/- cells compared to wild type macrophages (Fig. 6E).  The reduced 
UCP2 expression in macrophages, which leads to increased oxidative stress, 
would be predicted to lead to increased antioxidant protein expression.  
Paradoxically, in the FABP4/aP2-/-, UCP2 kd macrophages, expression of 
antioxidant enzymes are down-regulated.  This suggests UCP2 is involved in a 
more complex regulation of antioxidant expression.  Nevertheless, the loss of 
antioxidant capacity of UCP2 knock down is consistent with a previous report 
showing that UCP2 deficient mice have reduced antioxidant capacity (38).  
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Figure 9. Schematic model of the role of UCP2 up-regulation in 
macrophages.  Loss or inhibition of FABP4/aP2 increases the intracellular free 
fatty acid levels and induces expression of UCP2 via a PPAR-γ mediated 
pathway. Increased expression of UCP2 reduces oxidative stress in the 
mitochondrion, alleviates ER stress, inflammation and alters mitochondrial 
function in macrophages.  FFAi refers to intracellular free fatty acids.   
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Overall, the studies herein provide a mechanistic basis for the metabolic 
improvement in FABP4/aP2 deficient cells generated by either genetic or 
pharmacologic means.  Loss of FABP-FFA equilibrium is likely to increase the 
bioavailability of fatty acids, particularly unsaturated lipids that have the potential 
to increase the expression of UCP2.  Whether this mechanism exists in non-
macrophage cells and would pertain to the metabolic changes observed in 
FABP1, FABP2 or FABP3 null mice remains unknown (51).  However, it may be 
that FABP-dependent modulation of intracellular FFA levels and therefore UCP2 
expression may be a common property in many cell types.   
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SUMMARY  
Activation of pro-inflammatory macrophages plays an important role in the 
pathogenesis of insulin resistance, type 2 diabetes and atherosclerosis.  Prior 
work using high-fat fed mice has shown that ablation of the adipocyte fatty acid 
binding protein (FABP4/aP2) in macrophages leads to an anti-inflammatory state 
both in situ and in vivo and the mechanism is linked, in part, to increased 
intracellular monounsaturated fatty acids and the up regulation of UCP2.  Herein, 
we show that loss of FABP4/aP2 in macrophages additionally induces SIRT3 
expression and that monounsaturated fatty acids (C16:1, C18:1) lead to 
increased SIRT3 protein expression. Increased expression of SirT3 in 
FABP4/aP2 null macrophages occurs at the protein level with no change in SirT3 
mRNA.  When compared to controls, silencing of SIRT3 in Raw246.7 
macrophages leads to increased expression of inflammatory cytokines, inducible 
nitric oxide synthase (iNOS) and cyclooxygenase 2 (Cox2).  In contrast, loss of 
SIRT3 in FABP4/aP2 deficient macrophages attenuates the suppressed 
inflammatory signaling, reduced reactive oxygen (ROS) production, LPS induced 
mitochondrial dysfunction and increased fatty acid oxidation.  These results 
suggest that the anti-inflammatory phenotype of FABP4/aP2 null mice is 
mediated by increased intracellular monounsaturated fatty acids leading to the 
increased expression of both UCP2 and SirT3.   
 
 
 
	 70				
INTRODUCTION 
The prevalence of syndromes associated with obesity, including insulin 
resistance, hypertension and dyslipidemia have increased over the last decade 
(1,2).  High saturated fat or “western” diets and lack of exercise contribute to the 
epidemic of the metabolic syndrome (1,3,4).  At the molecular level, multiple 
pathways are involved in the pathogenesis of metabolic diseases including 
lipotoxicity and chronic inflammation in multiple tissues such as liver, muscle, and 
adipose (5-8).  Importantly, the infiltration and activation of immune cells such as 
T cells and macrophages play an essential role in the development of insulin 
resistance in adipose tissue (9,10).  Of these activated immune cells, 
macrophages play an integral role in the production of inflammatory cytokines as 
well as in the development of oxidative stress in adipose tissue (8).  
 
Macrophage lipid metabolism is critical in mediating adipose tissue inflammation 
and oxidative stress (11,12).  Work from our laboratory and many others have 
shown that the adipocyte fatty acid binding protein (FABP4, also know as aP2) 
plays an important role in the activation of macrophage inflammation (13-16).  
Ablation of FABP4/aP2 (AKO) in macrophages alone is sufficient to protect mice 
from diet induced atherosclerosis and dyslipidemia (14,16).  FABP4/aP2 is a 
small 15 kDa lipid chaperone involved in intracellular fatty acid trafficking but 
recently has been shown to be secreted into the extracellular environment 
(17,18).  Deficiency of FABP4/aP2 leads to suppressed inflammation, decreased 
ER stress and decreased NF-κB activation in macrophages (13,19,20).  
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Consistent with its role in ameliorating metabolic disorder in mice, a genetic 
variant at the promoter region of human FABP4/aP2, which leads to decreased 
expression, has been associated with reduced risk of coronary disease and type 
2 diabetes (21). 
 
Previous work has shown that the monounsaturated fatty acids palmitoleate and 
oleate are specifically increased in FABP4/aP2 deficient macrophages and are 
linked to the selective up regulation of uncoupling protein 2 (UCP2) (22).  
Increased expression of UCP2 in macrophages attenuates oxidative stress and 
reduces inflammatory signaling.  However, increased UCP2 expression alone is 
not sufficient to explain the increased fatty acid oxidation and resistance from 
lipopolysaccharide (LPS) induced mitochondrial dysfunction in FABP4/aP2 
deficient cells suggesting additional, unappreciated regulatory mechanisms.  
Herein we report that SIRT3, a member of the sirtuin family, is specifically up 
regulated in macrophages deficient in FABP4/aP2 and that monounsaturated 
fatty acids can induce SIRT3 up regulation at the protein level. The resulting 
increase of SIRT3 expression in macrophages is linked to suppressed 
inflammatory signaling as well as decreased reactive oxygen production and 
increased fatty acid oxidation in FABP4/aP2 deficient macrophages. 
Furthermore, SIRT3 up regulation protects FABP4/aP2 deficient macrophages 
from LPS induced mitochondrial dysfunction. 
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MATERIALS AND METHODS 
Cell culture.  Raw264.7 macrophages and Sirt3 knockdown Raw264.7 
macrophages were maintained in DMEM (Invitrogen) with 10% fetal bovine 
serum (FBS).  FABP4/aP2 knockout (AKO), wild type and Sirt3 knock down 
FABP4/aP2 deficient macrophages were maintained in RPMI 1640 (Invitrogen) 
with 5% FBS. 
 
Quantitative RT-PCR.  Total RNA was isolated using TRIzol reagent 
(Invitrogen). cDNA synthesis was performed by using iScript according to the 
manufacturer's protocol (Bio-Rad).  qRT-PCR amplification utilized a Bio-Rad 
CFX 96 real-time system with a SYBR green Supermix (Bio-Rad).  Transcription 
factor II E (TFIIE) was used as an internal control to normalize expression.  
Primer sequences are provided in Table 1.  
 
Silencing of Sirt3 in macrophages.  Raw264.7 macrophages were transduced 
with a short hairpin RNA (shRNA) lentivirus targeting either Green Fluorescent 
Protein (GFP) or SirT3 as described previously (23). Green fluorescent protein 
and Sirt3 (GenBank accession number NP_001120823) targeting sequences 
were obtained from Open Biosystems: Sirt3 (kd-1), 5′- 
CCGGGCCATCTTTGAACTTGGCTTTCTCGAGAAAGCCAAGTTCAAAGATGG
CTTTTTG-3’; GFP, 5′-AACGTACGCGGAATACTTCGA-3′.  Because SIRT3 is 
highly expressed in FABP4/aP2-/- macrophages (AKO) compared to wild type 
cells, two rounds of lentiviral infection was required to obtain significant silencing.  
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To that end, FABP4/aP2-/- macrophages were first transduced with kd-1 followed 
by an additional shRNA lentivirus (kd-2), 5′- 
CCGGCCTACTCCATATGGCTGACTTCTCGAGAAGTCAGCCATATGGAGTAG
GTTTTTG-3′.   
 
Stromal vascular fraction isolation.  Isolation of the stromal vascular fraction 
was performed as described in Xu et al. (29).  Briefly, epididymal fat pads were 
dissected from wild type and FABP4/aP2 knockout (AKO) mice (15 week old 
male C57BL/6J mice maintained on high saturated fat diet (BioServe F3282) for 
12 weeks), minced and digested in Krebs-Ringers-HEPES (KRH) buffer 
supplemented with type I collagenase (Worthington) and bovine serum albumin 
(BSA) for one hour at 37° C.  The mixture was filtered with 100-µm-pore-size 
nylon cell strainer (Falcon) to remove undigested tissue.  The stromal vascular 
fraction (SVF) was collected by centrifugation at 500 × g for 10 min.  After 
washing with KRH buffer, the SVF was either resuspended in TRIzol reagent for 
RNA isolation or in cell lysis buffer supplemented with protease inhibitors for 
protein assays. All experimental procedures using animals were reviewed and 
approved by the University of Minnesota Institutional Animal Care and Use 
Committee. 
 
Mitochondrial isolation and β-oxidation.  Mitochondrial isolation were carried 
out as described in Xu et al. (29).  Briefly, cells were scraped into ice-cold 
mitochondrial isolation buffer (20 mM Tris pH 7.4, 220 mM mannitol, 70 mM 
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sucrose, 1 mM EDTA, 0.1 mM EGTA) and supplemented with protease 
inhibitors.  Cells were then lysed with 20 strokes of a Dounce homogenizer and 
homogenates centrifuged at 700 × g for 10 min to remove nuclei and unbroken 
cells.  Mitochondria were pelleted by centrifugation at 10,000 × g for 15 min at 4° 
C.  Fatty acid oxidation was carried out as described previously (29). 
 
Measurement of ROS.  ROS production was measured by incubating cells with 
cell permeable 2', 7'-dichlorodihydrofluorescein diacetate (H2DCFDA) 
(Invitrogen).  Briefly, cells were washed with PBS, and incubated in 1 mL of KRH 
buffer (pH 7.4) with 10 µM final concentration of H2DCFDA for 30 minutes.  Then 
cells were washed with PBS and harvested into 300 µL KRH buffer.  Of each 
sample, 150 µL was loaded into a 96-well plate and fluorescence was measured 
using a microplate reader with excitation at 488 nm and emission at 535 nm. 
 
Immunoblot analysis.  Cells were lysed with radioimmunoprecipitation assay 
(RIPA) buffer supplemented with protease inhibitors (Calbiochem).  50 µg of 
protein from each sample were separated by SDS-PAGE and transferred to a 
polyvinylidene difluoride (PVDF) membrane.  After blocking with Odyssey 
blocking buffer (Li-Cor Biosciences), membranes were incubated with primary 
antibody overnight at 4° C. Membranes were washed and incubated with 
secondary antibody conjugated to Li-Cor IRDye for 1 h and visualized using 
Odyssey infrared imaging (Li-Cor Biosciences).  The primary antibodies used 
were anti-SIRT3 (Cell Signaling), anti-FABP4, anti-cyclooxygenase-2 (anti-Cox2) 
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(BD Transduction Laboratories), anti-inducible nitric oxide synthase (anti-iNOS) 
(BD Transduction Laboratories), anti-superoxide dismutase (anti-SOD2) (Cell 
Signaling), anti-long-chain acyl-CoA dehydrogenase (anti-LCAD) (Abcam), anti-
acetylated lysine (Cell Signaling), anti-β-actin (Sigma-Aldrich), and anti-ATP 
synthase-α subunit (MitoSciences). 
 
Immunoprecipitation.  Cells were washed twice with cold phosphate-buffered 
saline (PBS) and scraped into 1 ml of lysis buffer (20 mM Tris pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1mM EGTA, and 1% TritonX-100) supplemented with 
protease inhibitors and incubated for 10 minutes at 4° C.  After centrifugation at 
13,500 rpm for 10 minutes, supernatants were transferred to a new tube and the 
protein concentration was determined. 800 µg of protein lysates were pre-cleared 
by incubation with 30 µL protein G beads for 4 hours.  After centrifugation, 
supernatants were transferred to a new tube and 30 µL of a protein G bead slurry 
was added to each tube together with primary antibody or anti-rabbit IgG control 
antibody. After rotating overnight at 4° C, the pelleted beads were washed five 
times with 500 µL lysis buffer and resuspended in RIPA buffer.  Precipitated 
proteins were released from the IgG beads by boiling the samples for 10 minutes 
and loaded onto a SDS-PAGE gel for separation.  
 
Cellular respiratory assay.  Macrophage respiratory assay was performed on a 
XF24 Analyzer (Seahorse Biosciences).  Macrophages were plated on V7 
microplates at a density of 200,000 cells per well a day prior to the assay.  On 
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the day of the experiment, cells were treated either with vehicle or 
lipopolysaccharide (LPS) (100 ng/ml) for 6 hours.  The cells were then washed 
and incubated with assay media.  During the assay, cells were exposed to 
compounds in the following order: 2 µM oligomycin, 0.4 µM FCCP, and 4 µM 
antimycin A. 
 
Statistical analysis.  All results in the paper are expressed as the mean ± the 
standard error of the mean (± SEM). Statistical significance was determined 
using an unpaired two-tailed Student T-test. 
 
 
 
RESULTS 
 
Loss of FABP4/aP2 in macrophages increases SIRT3 expression.  Previous 
work by Xu et al. (22) as well as Erbay et al. and Coe et al. (20, 24) has shown 
that loss of FABP4/aP2 alters the intracellular level and composition of fatty acids 
in both macrophages and adipocytes resulting in the accumulation of 
monounsaturated fatty acids, particularly C16:1 and C18:1.  Interestingly, 
consumption of monounsaturated fatty acids, which are a major component of 
the Mediterranean diet, are associated with improved insulin sensitivity and 
decreased inflammation in both humans and mice (25).  In muscle, oleic acid 
treatment can activate the SIRT1-PGC1α (peroxisome proliferator-activated 
receptor γ coactivator 1-α) axis to increase fatty acid oxidation (26).  More 
recently, Liu et al. reported that in monocytes, SIRT1 activation leads to an 
increase of both expression and activation of SIRT3, thus restoring 
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immunometabolic homeostasis (27).  Therefore, we hypothesized that loss of 
FABP4/aP2 would increase SIRT3 expression via an increased level of 
monounsaturated fatty acids.  To test this hypothesis, we evaluated the protein 
level of SIRT3 in both wild type (WT) and FABP4/aP2-/- (AKO) macrophages 
derived from wild type and FABP4/aP2-/- mice, respectively.  SIRT3 expression in 
FABP4/aP2-/- macrophages was more than doubled compared to that in wild type 
(Figure 1A).  To further confirm that the loss of FABP4/aP2 leads to up regulation 
of SIRT3 in macrophages, we isolated the stromal vascular fraction (SVF) from 
visceral adipose tissue of male high fat diet (HFD) fed WT and AKO mice.  The 
level of SIRT3 was increased about three fold in AKO-SVF compared to that of 
wild type (Figure 1B).  Interestingly, the level of Sirt3 mRNA did not change 
between wild type and FABP4/aP2-/- cell lines or SVF fractions indicating the 
difference of SIRT3 expression came from regulation at the translational or post-
translational level (Figure 1C and D).  To explore the potential role of 
monounsaturated fatty acids on SIRT3 expression, Raw264.7 macrophages 
were treated with either MUFAs (palmitoleate and oleate) or palmitate. The 
results showed that MUFA treatment could induce SIRT3 expression in 
macrophages but not the saturated fatty acid palmitate (Figure 1E).  Similar to 
the results in experimental mice, the increase in protein was not accompanied by 
an increase in SirT3 mRNA (Figure 1F). Taken together, these results suggest 
that the increased monounsaturated fatty acids, due to the genetic ablation of 
FABP4/aP2, may be responsible for the increased SIRT3 expression in 
macrophages.  
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Figure 1 Loss of FABP4/aP2 increases SIRT3 expression.  (A) SIRT3 protein 
level normalized to ATP5α in the mitochondrial fraction of wild type (WT) and 
FABP4/aP2-/- (AKO) macrophages. (B) SIRT3 protein level normalized to β-actin 
in the stromal vascular fraction of epididymal adipose tissue obtained from high 
fat diet (HFD) fed WT and FABP4/aP2 (AKO) null mice. (C) SIRT3 mRNA level in 
WT and AKO macrophages. (D) SIRT3 mRNA level in the stromal vascular 
fraction of epididymal adipose tissue obtained from HFD fed WT and AKO mice. 
(E) SIRT3 protein expression in Raw264.7 macrophages treated with 300 µM 
palmitate, palmitoleate, or oleate for 36 hours. (F) SIRT3 mRNA level in 
Raw264.7 macrophages treated with 300 µM palmitate, palmitoleate, or oleate 
for 36 hours. Fatty acids were added in complex to bovine serum albumin at a 
molar ratio of 4:1 (FFA/BSA).  (*p<0.05, **p<0.01, n=3-6 per group) 
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SIRT3 expression is anti-inflammatory in macrophages.  Diet induced obesity 
is accompanied by decreased SIRT3 expression in multiple tissues including 
liver, skeletal muscle, heart, and pancreas (28-32).  Both genetic knock out 
animal models and clinical studies of type 2 diabetics have shown the important 
role of SIRT3 in maintaining insulin sensitivity in various tissues and organs 
(29,30,32).  However, the role of SIRT3 in tissue macrophages has not been well 
defined, having been studied primarily in a sepsis model (27). To illustrate the 
relationship between SIRT3 expression and macrophage inflammation, we 
silenced Sirt3 in Raw264.7 macrophages by infecting cells with lentivirus 
encoding a SirT3 targeted shRNA.  The knockdown cell line expressed about 
50% of SIRT3 protein compared to the control cells (Figure 2A).  Co-treatment of 
Sirt3 silenced macrophage cells with LPS and interferon γ (IFNγ) induced a 
significantly higher level of iNOS expression in Sirt3 knockdown Raw264.7 
macrophages compared to control cells (Figure 2B).  In addition, macrophages 
treated with palmitate or palmitoleate, which have been shown to prime 
macrophages towards a pro- or anti-inflammatory state, respectively, regulated 
inflammatory marker genes.   Decreased expression of SIRT3 led to increased 
palmitate induced Cox2 expression, and compromised the ability of palmitoleate 
to reduce Cox2 expression (Figure 2C).  Additionally, Sirt3 knockdown Raw264.7 
macrophages expressed higher transcript levels of the inflammatory cytokines 
TNFα and MCP1 (Figure 2D).  In summary, loss of SIRT3 in macrophages 
results in an elevated inflammatory state.  
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Figure 2.  Loss of SIRT3 is proinflammatory in macrophages.  (A) SIRT3 
expression in SIRT3 knockdown Raw264.7 macrophages (Sirt3 kd) and control 
knockdown cells (Ctl). (B) iNOS abundance measured by western blot in Ctl and 
Sirt3 kd macrophages co-treated with LPS (100 ng/ml) and IFNγ (10U) for 14 
hours. (C) Cox2 abundance in palmitate or palmitoleate (300 µM) (4:1 fatty acid 
to BSA) treated Ctl and Sirt3 kd macrophages. (D) mRNA levels of Sirt3, Tnfα 
and Mcp1 in Ctl and Sirt3 kd macrophages. (*p<0.05, **p<0.01, n=3 per group) 
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SIRT3 mediates the decreased inflammatory signaling in FABP4/aP2-/- 
macrophages.  Loss of FABP4/aP2 reduces macrophage inflammatory markers 
such as Cox2 and iNOS (26).  In order to determine if SIRT3 plays a role in the 
suppressed inflammatory signaling in FABP4/aP2-/- macrophages, we silenced 
SIRT3 (sirt3kd) in both wild type (WT) and FABP4/aP2-/-  (AKO) backgrounds 
(Figure 3A).  LPS treatment induced higher expression of Cox2 in both WT-
sirt3kd and AKO-sirt3kd macrophages compared to their corresponding control 
cell lines. The basal expression of SIRT3 was similar between wild type and 
AKO-sirt3 kd macrophages, however the expression of Cox2 was still much 
lower in AKO-sirt3kd (Figure 3B).  Therefore, SIRT3 expression in AKO is 
partially responsible for the reduced inflammatory signaling. Similarly, knockdown 
of Sirt3 in FABP4/aP2-/- cells dramatically increased LPS and IFNγ induced iNOS 
expression (Figure 3C).  Additionally, genetic knockdown of Sirt3 increased the 
basal expression of the inflammatory cytokines, MCP1, TNFα, and MMP9 mRNA 
in WT and FABP4/aP2-/- cells compared to their respective controls (Figure 3D).  
In conclusion, increased SIRT3 expression in FABP4/aP2-/- macrophages is at 
least partially responsible for the reduced inflammatory signaling.  
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Figure 3. SIRT3 up regulation mediates the decreased inflammation in 
FABP4/aP2-/- macrophages.  (A) SIRT3 protein expression in the mitochondrial 
fraction of WT-ctl, WT-sirt3 kd, AKO-ctl, and AKO-sirt3 kd macrophages. (B) 
Cox2 abundance determined by western blot in WT-ctl, WT-sirt3 kd, AKO-ctl, and 
AKO-sirt3 kd cells treated with LPS (100 ng/ml) for 16 hours. (C) iNOS 
abundance determined by western blot in WT-ctl, AKO-ctl and AKO-sirt3 kd cells 
co-treated with LPS+IFNγ for 18 hours. (D) mRNA level of SIRT3 and 
inflammatory cytokines in WT-ctl, WT-sirt3 kd, AKO-ctl, and AKO-sirt3 kd 
macrophages. (*p<0.05, **p<0.01, n=3-6 per group) 
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SIRT3 mediates the decreased inflammatory signaling in FABP4/aP2-/- 
macrophages.  Loss of FABP4/aP2 reduces macrophage inflammatory markers 
such as Cox2 and iNOS (13).  In order to determine if SIRT3 plays a role in the 
suppressed inflammatory signaling in FABP4/aP2-/- macrophages, we silenced 
SIRT3 (sirt3kd) in both wild type (WT) and FABP4/aP2-/-  (AKO) backgrounds 
(Figure 3A).  LPS treatment induced higher expression of Cox2 in both WT-
sirt3kd and AKO-sirt3kd macrophages compared to their corresponding control 
cell lines. The basal expression of SIRT3 was similar between wild type and 
AKO-sirt3 kd macrophages, however the expression of Cox2 was still much 
lower in AKO-sirt3kd (Figure 3B).  Therefore, SIRT3 expression in AKO is 
partially responsible for the reduced inflammatory signaling. Similarly, knockdown 
of Sirt3 in FABP4/aP2-/- cells dramatically increased LPS and IFNγ induced iNOS 
expression (Figure 3C).  Additionally, genetic knockdown of Sirt3 increased the 
basal expression of the inflammatory cytokines, MCP1, TNFα, and MMP9 mRNA 
in WT and FABP4/aP2-/- cells compared to their respective controls (Figure 3D).  
In conclusion, increased SIRT3 expression in FABP4/aP2-/- macrophages is at 
least partially responsible for the reduced inflammatory signaling.  
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Figure 4. SIRT3 expression protects macrophages from LPS induced 
mitochondrial dysfunction.  (A) Oxygen consumption rate in WT-ctl and WT-
sirt3 kd macrophages treated with or without LPS (100 ng/ml) for 6 hours 
(oligomycin, 2 µM; FCCP, 0.4 µM; antimycin, 4 µM ). (B) Maximum respiration in 
WT-ctl and WT-sirt3 kd macrophages treated with or without LPS (100 ng/ml) for 
6 hours. (C) Coupling efficiency in WT-ctl and WT-sirt3 kd macrophages treated 
with or without LPS (100 ng/ml) for 6 hours. (D) Oxygen consumption rate in 
AKO-ctl and AKO-sirt3 kd macrophages treated with or without LPS (100 ng/ml) 
for 6 hours (oligomycin, 2 µM; FCCP, 0.4 µM; antimycin, 4 µM ).  (E) Maximum 
respiration in AKO-ctl and AKO-sirt3 kd macrophages treated with or without LPS 
(100 ng/ml) for 6 hours. (F) Coupling efficiency in AKO-ctl and AKO-sirt3 kd 
macrophages treated with or without LPS (100 ng/ml) for 6 hours. (*p<0.05, 
**p<0.01, n=5 per group) 
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SIRT3 expression mediates the protective effect of FABP4/aP2 deficiency 
on LPS induced mitochondrial dysfunction.  Genetic ablation of FABP4/aP2 
has been shown to protect macrophages from LPS dependent loss of maximum 
respiration capacity, independent of uncoupling protein 2 expression (22).  In 
order to determine if the increased expression of SIRT3 in FABP4/aP2-/- 
macrophages could mediate the suppression of LPS induced mitochondrial 
dysfunction, both WT-sirt3kd and AKO-sirt3kd, as well as their control cells, were 
treated with LPS for 6 hours and cellular respiration was measured.  Consistent 
with our previous report (22), LPS treatment induced a decrease of maximum 
respiration in wild type cells, while FABP4/aP2-/- macrophages were protected 
from this effect (Figures 4A-B and D-E). Knockdown of Sirt3 rendered wild type 
macrophages more susceptible to a LPS induced decrease of maximum 
respiration (Figure 4B). Moreover, knockdown of Sirt3 in FABP4/aP2-/- 
macrophages led to a similar reduction of maximum respiration by LPS 
treatment, thus eliminating the protection seen in the FABP4/aP2-/- macrophages 
(Figure 4E). Interestingly, coupling efficiency was increased after Sirt3 
knockdown in wild type and FABP4/aP2-/- macrophages and decreased in Sirt3 
knockdown cells following LPS treatment (Figures 4C and F). No difference of 
basal respiration or ATP turnover was observed (data not shown).  Therefore, up 
regulation of SIRT3 in FABP4/aP2-/- macrophages is responsible for changes in 
mitochondrial respiration in response to LPS treatment. 
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SIRT3 expression is responsible for fatty acid oxidation and ROS 
production in macrophages independent of lysine acetylation changes.  
Among the seven members in the sirtuin family, SIRT3 plays a major role in 
regulating mitochondrial function by affecting various aspects of mitochondrial 
metabolism, including mitochondrial respiration, fatty acid oxidation, and the 
tricarboxylic acid cycle flux (TCA cycle) (33-35). Consistent with the report that 
SIRT3 regulates fatty acid oxidation (34), Sirt3 knockdown in FABP4/aP2-/- 
macrophages decreased fatty acid oxidation (Figure 5A). Another prominent role 
of SIRT3 is controlling reactive oxygen species (ROS) production (33). 
Consistently, knockdown of Sirt3 increased ROS production in Raw264.7 and 
wild type macrophages (Figure 5B and C).  Since our previous work has shown 
that FABP4/aP2-/- macrophages have a significantly lower level of oxidative 
stress (22), we speculated that the increased SIRT3 expression may be 
responsible for the decreased ROS level.  Consistent with our previous report, 
the ROS level was significantly lower in FABP4/aP2-/- macrophages compared to 
that in the wild type (Figure 5C).  Upon LPS stimulation, there was a significant 
increase of ROS in wild type, but not FABP4/aP2-/- macrophages.  Importantly, 
upon LPS stimulation, AKO-sirt3kd cells had a significant increase in ROS 
production compared to AKO macrophages, however the ROS levels were still 
considerably lower than that in wild type macrophages in response to LPS 
stimulation (Figure 5C).  These data indicate up regulation of SIRT3 is at least 
partially responsible for the decreased ROS in FABP4/aP2-/- macrophages in 
response to LPS treatment.  Despite the increased SIRT3 expression in 
	 89				
FABP4/aP2-/- macrophages, we did not detect any substantive difference in the 
mitochondrial acetylome or the acetylation of classic SIRT3 targets, LCAD and 
SOD2 (Figures 5D-F).  
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Figure 5. Increased SIRT3 expression mediates increased β-oxidation and 
decreased oxidative stress in FABP4/aP2-/- macrophages independent of 
protein acetylation. (A) β-oxidation measured in AKO-ctl and AKO-sirt3 kd 
macrophages. (B) ROS measured by H2DCFDA in Control and Sirt3 kd 
Raw264.7 macrophages. (C) ROS measured by H2DCFDA in WT-ctl, WT-sirt3 
kd, AKO-ctl, and AKO-sirt3 kd macrophages treated with or without LPS (100 
ng/ml) for 6 hours. (D) Mitochondrial protein acetylation in WT and AKO 
macrophages. (E) Analysis of acetylated and total LCAD following 
immunoprecipitation from WT and AKO macrophages. (F) Evaluation of 
acetylated and total SOD2 immunoprecipitated from WT and AKO macrophages. 
(*p<0.05, **p<0.01, n=3-6 per group)  
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DISCUSSION 
Insulin resistance in peripheral tissues such as liver, adipose, and muscle is a 
major feature in the pathogenesis of cardiovascular disease, fatty liver, and type 
2 diabetes (1,5).  The progression of insulin resistance is accompanied with 
macrophage infiltration and chronic inflammatory activation in multiple tissues 
(12,36-38).  Mouse models which either reduce macrophage recruitment in 
adipose tissue or suppress macrophage inflammation have been show to protect 
the animal from high fat diet induced insulin resistance (39-41).  One of the most 
well characterized mouse models that affect these inflammatory events is genetic 
deletion of FABP4/aP2. Despite a similar level of adiposity, FABP4/aP2-/- mice 
are protected from diet induced insulin resistance (42). Interestingly, macrophage 
specific deletion of FABP4/aP2 is sufficient to prevent the development of 
atherosclerosis in the ApoE-deficient mouse model (14).  More detailed studies 
have shown that loss of FABP4/aP2 could suppress inflammatory signaling in 
macrophages, which is a major reason for the metabolic benefits of FABP4/aP2 
deficiency (13,16,43,44).  Recent work from our laboratory has shown that 
induction of UCP2 expression is a major mediator of the decreased inflammation 
and endoplasmic reticulum stress responses observed in FABP4/aP2-/- 
macrophages (22). However, up regulation of UCP2 does not explain the 
increased fatty acid oxidation and improved mitochondrial function in 
FABP4/aP2-/- macrophages.  Previous reports demonstrating a MUFA-SIRT1-
PGC1α-SIRT3 axis, as well as our own observation that monounsaturated fatty 
acids are specifically increased in FABP4/aP2-/- macrophages, led us to 
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speculate that SIRT3 expression might be altered in FABP4/aP2-/- macrophages 
(26,27). Indeed, the results herein showed a dramatic increase of SIRT3 protein, 
but not mRNA, following loss of macrophage FABP4/aP2. Additionally, silencing 
of Sirt3 in FABP4/aP2-/- macrophages decreased fatty acid oxidation.  More 
importantly, our results also demonstrated for the first time that MUFAs, but not 
palmitate, could induce SIRT3 protein expression in macrophages.  By knocking 
down Sirt3 in macrophages, the results here revealed an important role of SIRT3 
in the suppression of macrophage inflammation. Induction of SIRT3 is required 
for the anti-inflammatory role of palmitoleate, as knockdown of Sirt3 
compromised the reduction of Cox2 expression caused by palmitoleate 
treatment.  
 
In parallel with the identification of UCP2 as a major mediator of the decreased 
inflammation in FABP4/aP2-/- macrophages, the loss of SIRT3 also restored the 
inflammation in FABP4/aP2 deficient cells similar to wild type macrophages.  
Interestingly, SIRT3 expression has been shown to be correlated with UCP2 
levels in hepatocytes cultured in high glucose and in this system, inhibition of 
SIRT3 also leads to decreased UCP2 expression (45).  Therefore, it is likely that 
SIRT3 acts as an upstream regulator of UCP2, and exerts some of its action by 
suppressing inflammation in macrophages through UCP2.  
 
SIRT3 localizes primarily to mitochondria and regulates the activity of a number 
of enzymes involved in some major metabolic pathways, including tricarboxylic 
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acid cycle, the urea cycle, and fatty acid metabolism (33-35).  Given the 
prominent role of SIRT3 in mitochondrial function, it was not surprising to find 
that the up regulation of SIRT3 is an important contributor to the improved 
mitochondrial function observed in FABP4/aP2-/- macrophages (22). While 
FABP4/aP2-/- macrophages are protected from LPS induced loss of maximum 
respiration capacity, knockdown of SIRT3 potentiated LPS induced mitochondrial 
dysfunction.  Consistent with SIRT3’s role as a suppressor of oxidative stress, 
loss of SIRT3 increased ROS production both basally and in response to LPS in 
macrophages.  
 
Paradoxically, despite the dramatic up regulation of SIRT3, we were not able to 
detect any difference of global mitochondrial protein lysine acetylation or in the 
acetylation status of classic targets of SIRT3 such as LCAD and SOD2.  One 
potential explanation is that SIRT3 exerts its role in inflammation, ROS control, 
and mitochondrial function through a mechanism other than protein deacetylase 
activity in macrophages (46).  It is also possible that the acetylation status of the 
SIRT3 targets analyzed here are affected by other pathways in addition to 
SIRT3.  Generally, SIRT3 is considered as a ROS suppressor mainly by 
regulating SOD2 acetylation status (47).  However, we did not detect any 
difference of SOD2 expression or acetylation between wild type and FABP4/aP2-
/- macrophages (Figure 5).  While we speculate that SIRT3 serves as an 
oxidative stress suppressor in macrophages by regulating UCP2 expression, 
further work is required to validate this point. 
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In summary, the results presented herein demonstrate that SIRT3 is up regulated 
in FABP4/aP2 deficient macrophages, potentially via increased levels of 
palmitoleic acid.  The increased SIRT3 expression mediates decreased 
inflammation and intracellular ROS as well as the improved mitochondrial 
function in FABP4/aP2-/- macrophages.  However, increased SIRT3 expression 
did not affect global acetylation status of mitochondrial protein in FABP4/aP2-/- 
macrophages. 
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SUMMARY  
Obesity-linked metabolic disease is mechanistically associated with the 
accumulation of proinflammatory macrophages in adipose tissue leading to 
increased reactive oxygen species (ROS) production and low-grade, chronic 
inflammation. Previous work has demonstrated that deletion of the adipocyte 
fatty acid-binding protein (FABP4/aP2) uncouples obesity from inflammation via 
up-regulation of the uncoupling protein 2 (UCP2).  Herein we demonstrate that 
ablation of FABP4/aP2 regulates systemic redox capacity, reduces cellular 
protein sulfhydryl oxidation and in particular, oxidation of mitochondrial protein 
cysteine residues.  Coincident with the loss of FABP4/aP2 is the up-regulation of 
antioxidants superoxide dismutase (SOD2), catalase, methionine sulfoxide 
reductase A and the 20S proteasome subunits PSMB5 and αβ.  Reduced 
mitochondrial protein oxidation in FABP4/aP2-/- macrophages attenuates the 
mitochondrial unfolded protein response (mtUPR) as measured by expression of 
heat shock protein 60, Clp protease and Lon peptidase 1.  Consistent with a 
diminished mtUPR, FABP4/aP2-/- macrophages exhibit reduced expression of 
cleaved caspase 1 and NLRP3.  Secretion of IL-1β, in response to 
inflammasome activation, is ablated in FABP4/aP2-/- macrophages as well as in 
FABP4/aP2-inhibitor treated cells but partially rescued in FABP4/aP2 null 
macrophages when UCP2 is silenced.  Collectively, these data offer a novel 
pathway whereby FABP4/aP2 regulates macrophage redox signaling and 
inflammasome activation via control of UCP2 expression. 
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INTRODUCTION 
Obesity is linked with a variety of metabolic diseases including type II diabetes, 
dyslipidemia and cardiovascular disease.  Accumulation of visceral adipose 
tissue (VAT) is critical for disease development as it contains inflammatory 
macrophages that secrete cytokines, chemokines and other signaling molecules 
leading to both local and systemic effects (1, 2). Increased abundance of reactive 
oxygen species (ROS) is one critical consequence of adipose inflammation and 
hydrogen peroxide (H2O2) serves as a secondary messenger in various 
immunometabolic signaling processes (3, 4).  H2O2 leads to reversible cysteine 
and methionine oxidation that alters protein activity and/or interactions (5, 6).  
Moreover, chronically elevated oxidative species diminish the cellular pool of 
chemical antioxidants (GSH and NADPH) leading to a variety of 
pathophysiologies (7-10). Sustained protein oxidation not only leads to 
dysregulated signaling cascades, but also protein unfolding and potentially 
aggregation (11, 12).  Multiple quality control systems exist in the endoplasmic 
reticulum and mitochondria to prevent oxidative damage and protein aggregation 
(4, 13-15). Despite this, the mitochondria in particular is vulnerable to sustained 
oxidative stress due to the high capacity for reactive oxygen species synthesis in 
the electron transport chain (16-18).  Mitochondrial uncoupling proteins are one 
such mechanism to dissipate the proton gradient across the inner membrane and 
reduce oxidative stress (19).   
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In macrophages, one major consequence of mitochondrial dysfunction 
associated with metabolic disease is the activation of the inflammasome and 
secretion of IL-1β (20). Secretion of IL-1β from macrophages typically involves 
multiple inputs and minimally requires activation of the NF-κB pathway resulting 
in expression of inflammasome complex including pro-caspase-1, NACHT, LRR 
and PYD domains-containing protein 3 (NLRP3) and pro-IL-1β.  Secondary 
signaling (e.g., ROS, unfolded protein response) leads to the auto-cleavage of 
pro-caspase-1 followed by processing of pro-IL-1β to the mature IL-1β and its 
subsequent secretion (21-23).  
 
A variety of mouse models have been developed to interrogate the molecular 
relationship between obesity, inflammation and metabolic disease.  Of these, the 
FABP4/aP2 knockout mouse has been intensely studied as a paradigm for 
regulatory systems linking lipid metabolism to inflammation.  In the FABP4/aP2 
system the loss of this intracellular fatty acid binding protein from macrophages 
results in an anti-inflammatory phenotype in both animal and cell based models 
(3, 24-27).  At the molecular level, loss of FABP4/aP2 attenuates nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) signaling, reduces c-Jun 
N-terminal kinase (JNK) phosphorylation, diminishes inflammatory cytokine 
secretion and polarizes cells from the classically activated M1 phenotype to the 
alternatively activated M2 (28, 29). Recently, Xu et al., reported that ablation of 
FABP4/aP2 in macrophages improves mitochondrial function and attenuates NF-
κB signaling via monounsaturated fatty acid induction of UCP2 and sirtuin-3 (3, 
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28).  However, the molecular mechanisms that link the increased expression of 
UCP2 to diminished inflammatory cytokine synthesis are unclear.  To that end, in 
this report we describe novel findings that demonstrate the FABP4/aP2–UCP2 
axis regulates mitochondrial redox biology, the mitochondrial unfolded protein 
response and activation of the inflammasome.   
 
MATERIALS AND METHODS 
Mice.  Male C57BL/6J wild type (WT) and whole body knockout of FABP4/aP2 
(abbreviated as AKO) mice were fed ad libitum a high saturated fat (lard) diet 
(BioServe F3282, Flemington, NJ) from weaning for 12 weeks.  Mice were used 
between 15-16 weeks of age and weighed 40-50 g.  Such high fat fed mice 
developed insulin resistance as measured by impaired insulin and glucose 
tolerance, hyperinsulinemia, increased hepatic glucose output and elevated 
lipolysis (86).  All experimental procedures using animals were reviewed and 
approved by the University of Minnesota Institutional Animal Care and Use 
Committee. 
 
Cell culture.  A variety of stable cell lines linked to FABP4/aP2 biology reported 
herein were immortalized from bone marrow derived macrophages of chow fed 
WT and AKO C57BL/6J mice as previously reported (70). These include stable 
macrophage cells from wild type C57BL/6J mice (WTMΦ) and FABP4/aP2 null 
mice (AKOMΦ), wild type or AKO macrophages expressing eGFP (WT-eGFPMΦ, 
AKO-eGFPMΦ), and AKO macrophages in which UCP2 has been silenced (AKO-
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UKDMΦ). All the above-mentioned macrophage cells were maintained in RPMI 
1640 (Invitrogen, Carlsbad, CA) with 5% fetal bovine serum. Raw 264.7 control 
and UCP2 knockdown cells (Raw-eGFP and Raw-UKD) cells were cultured in 
Dulbecco’s’ modified Eagle’s medium (DMEM, Invitrogen, Carlsbad, CA) with 
10% fetal bovine serum (29). Bone marrow derived macrophages (BMDMs, 2 X 
106 cells) were isolated from C57BL/6J mice, plated and maintained in Iscove’s 
Modified Dulbecco’s Medium (Invitrogen, Carlsbad, CA), 10% FBS and 10ng/mL 
macrophage colony-stimulating factor (M-CSF) for one week prior to stimulation 
(13).  
 
Quantitative RT-PCR.  Total RNA was isolated using TRIzol reagent (Invitrogen, 
Carlsbad, CA) from WT and AKO macrophage cell lines.  cDNA synthesis was 
performed by using iScript according to the manufacturer's protocol (Bio-Rad, 
Hercules, CA).   qRT-PCR amplification utilized a Bio-Rad CFX 96 real-time 
system with a SYBR green Supermix.  Transcription factor II E (TFIIE) and 
TATA-binding protein (TBP) were used as internal controls to normalize 
expression.  Primer sequences can be found in Table I.  
 
Stromal vascular fraction isolation.  Isolation of stromal vascular fraction was 
performed as described in Xu et al (29). Visceral fat pads were dissected from 
wild type and FABP4/aP2 knockout mice (WTSVF, AKOSVF), minced and digested 
in Krebs-Ringers-HEPES (KRH) buffer supplemented with type I collagenase 
(Worthington, Lakewood, NJ) and bovine serum albumin (BSA) for one hour at 
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37° C.  Undigested tissue was removed by filtering the mixture through 100-µm-
pore-size nylon cell strainer (Fischer Scientific, Walthman, MA).  The stromal 
vascular fraction (SVF) was collected by centrifugation at 500 × g for 10 min 
followed by two washes with KRH buffer. The newly isolated SVF was then either 
resuspended in TRIzol reagent for RNA isolation, in cell lysis buffer 
supplemented with protease inhibitors for protein assays, or precipitated with 
20% TCA for cysteine oxidation detection.  
 
Mitochondrial isolation.  Mitochondrial isolation was carried out as described in 
Xu et al (29). Tissue was placed in ice-cold mitochondrial isolation buffer (20 mM 
Tris pH 7.4, 220 mM mannitol, 70 mM sucrose, 1 mM EDTA, 0.1 mM EGTA) and 
supplemented with protease inhibitors.  The tissue was then lysed with 7 strokes 
of a Dounce homogenizer and homogenates centrifuged at 900 × g for 10 min to 
remove nuclei and unbroken cells. To pellet the mitochondria, the supernatant 
was centrifuged at 10,000 × g for 15 min at 4° C.   
 
Hydrogen peroxide measurements.  Amplex® Red Hydrogen 
Peroxide/Peroxidase Assay Kit (Invitrogen, Carlsbad, CA) was used to measure 
hydrogen peroxide following the manufacturer’s instructions.  
 
Immunoblot analysis. Cells were lysed with radioimmunoprecipitation assay 
(RIPA) buffer supplemented with protease inhibitors (Calbiochem, Darmstadt, 
Germany).  25-50 µg of protein from each sample were separated by SDS-PAGE 
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and transferred to a polyvinylidene difluoride (PVDF) membrane as measured by 
a bicinchoninic acid (BCA) assay.  After blocking with Odyssey blocking buffer 
(LI-COR Biosciences, Lincoln NE), membranes were incubated with primary 
antibody overnight at 4° C. Membranes were washed and incubated with 
secondary antibody conjugated to Li-Cor IRDye for 1 hr and visualized using 
Odyssey infrared imaging (Li-Cor Biosciences, Lincoln NE).  The primary 
antibodies used were anti-catalase (abcam, Cambridge, MA), IRDye® 800CW 
Streptavidin (cysteine oxidation, LI-COR, Lincoln, NE), anti-PSMB5 (abcam, 
Cambridge, MA), anti-20S αβ (abcam, Cambridge, MA), anti-NLRP3 (adipogen, 
San Diego, CA), anti-caspase-1 (abcam, Cambridge, MA), anti-methionine 
sulfoxide reductase A (abcam, Cambridge, MA), anti-β-actin (Sigma-Aldrich, St. 
Louis, MO), anti-super oxide dismutase 2 (cell signaling, Beverly, MA), anti-
LonP1 (abcam, Cambridge, MA), anti-ClpP (abcam, Cambridge, MA), anti-
HSP60 (abcam, Cambridge, MA).  
 
Detecting global cysteine oxidation. Wild type and AKO SVF, mitochondria 
isolates or macrophage cell line lysates were directly precipitated with 20% TCA 
for 2 hours at 4° C.  The pellets were subsequently washed with 10% TCA, 
5%TCA and 75% ice-cold acetone then resuspended in labeling buffer (200 mM 
Tris pH 8.5, 5 mM EDTA, 0.05% SDS and 6 M Urea). The lysates were labeled 
with 100 mM iodoacetamide for 15 minutes at room temperature followed by 
addition of 100% TCA (20% final) and maintained at 4° C overnight. The cell 
pellets were washed again and resuspended in reducing buffer (40 mM sodium 
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arsenite, 150 mM Tris pH 7.4, 2.5% SDS) along with 200 uM biotin-maleimide 
and incubated for 1hr at 50° C. Each sample was measured for protein 
concentration with a BCA assay and proteins were separated by SDS-PAGE. 
The membrane was placed in blocking buffer overnight at 4° C and incubated for 
1hr in IRDye® 800CW Streptavidin to detect the cysteine conjugated biotin 
residues (cysteine oxidation).  
 
ELISA analysis. IL-1β was detected in the media of macrophage cell lines or 
bone marrow derived macrophages treated with either 30 uM HTS01037 for 4 hr, 
2 uM or 5 uM cyclosporin A for 1 hr, 500 ng/mL LPS for 4 hr, 10 uM MG132 for 2 
hr or 2 mM ATP for 1 hr using an ELISA kit (BD Biosciences, San Jose, CA).  
 
Statistical analysis.  All results are expressed as standard error of the mean (± 
SEM).  For studies using the stable wild type and AKO cell lines, results are 
presented from a sample size of three or more and were repeated in at least 
three independent experiments.  For studies using cells derived from the mouse 
stromal vascular fraction or bone marrow derived macrophages, studies are 
reported from experiments performed at least 3 times with a sample size of 4-6 
per experiment.  Statistical significance was determined using an unpaired two-
tailed Student t test.  
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RESULTS 
Loss of FABP4/aP2 in macrophages induces UCP2 and reduces oxidative 
stress.  Prior work from Xu et al. has shown that loss of FABP4/aP2 results in 
elevated intracellular abundance of monounsaturated fatty acids (C16:1 and 
C18:1) and up regulates the expression of UCP2.  Moreover, treatment of 
RAW264.7 cells with exogenous palmitoleic or oleic acid, but not palmitate or 
stearate, increased the expression of UCP2 leading to the model that 
monounsaturated fatty acids increase UCP2 expression (3). As shown in Figure 
1A, UCP2 protein was significantly increased in FABP4/aP2 null macrophages 
(AKOMΦ) compared to control macrophages from wild type C57BL/6J mice 
(WTMΦ).  Furthermore, macrophage cells that lack FABP4/aP2 either via genetic 
means (AKO cells) or treated with an FABP4/aP2 inhibitor (HTS01037, (26)) 
exhibit significantly reduced hydrogen peroxide levels (Figure 1B). AKO 
macrophages were also protected from the increase in hydrogen peroxide when 
treated with 100 ng/mL LPS for 24 hours (Figure 1C).  The reduction in hydrogen 
peroxide was lost when UCP2 was silenced in either AKO macrophages (AKO-
UKDMΦ) or Raw 267.4 macrophages (Raw-UKD). In addition, treatment of 
HTS01037 could not lower hydrogen peroxide levels in Raw-UKD cells as was 
observed in control Raw 264.7 macrophages (Raw-eGFP, Figure 1D-E). These 
data collectively indicate UCP2 is modulating the affect of reduced hydrogen 
peroxide in FABP4 null macrophages.  This is consistent with previous studies 
that UCP2 can reduce ROS levels, independently from proton uncoupling (19, 
32).    
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Figure 1: Loss of FABP4/aP2 decreases hydrogen peroxide in a UCP2 
dependent manner. (A) UCP2 protein in WT and AKO macrophage cell lines 
(macrophage cells lines are denoted by WTMΦ and AKOMΦ). (B) Hydrogen 
peroxide levels measured in WT macrophages with or without 4 hr treatment with 
30 µM HTS01037 compared to that in AKO macrophages. (C) Hydrogen 
peroxide levels in WT and AKO macrophages treated with or without 100 ng/mL 
LPS for 24 hours.  (D) Hydrogen peroxide in WT and AKO control cells (WT-
eGFPMΦ, AKO-eGFPMΦ) and in UCP2 silenced AKO cells (AKO-UKDMΦ). (E) 
Hydrogen peroxide measured in Raw 264.7 control cells (Raw-eGFP) and UCP2 
silenced Raw 264.7 cells (Raw-UKD) with or without treatment of 30 µM 
HTS01037 for 16 hours. (*p <0.05, **p < 0.005, ***p < 0.0005)  
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Since the redox environment is different between cultured WT and AKO 
macrophages, the redox status of cysteine residues in different fractions of the 
visceral adipose tissue (VAT) of experimental animals was measured using the 
biotin-switch assay.  As shown in Figure 2A, when WT mice were maintained on 
a high saturated fat diet for 12 weeks, the level of mitochondrial cysteine 
oxidation in the VAT was markedly greater than in mice maintained on a low fat, 
chow control diet.  When such modification was evaluated in WT mice and 
compared to FABP4/aP2 null animals (maintained on a high saturated fat diet), 
mitochondrial cysteine oxidation levels were significantly blunted in the AKO 
mice, even though these mice were as obese as the wild type controls (Figure 
2B).  Moreover, the proteins from the whole cell lysates of the VAT derived 
stromal vascular fraction (SVF) enriched for macrophages, also exhibited a 
reduction in cysteine oxidation from AKO mice compared to the control animals 
(WTSVF and AKOSVF, Figure 2C). Finally, when the macrophage cell lines were 
treated with 100 ng/mL LPS for 24 hours, there was less cysteine oxidation in the 
whole cell lysate of AKO macrophages, albeit to a lesser degree as observed in 
the tissue samples (Figure 2D). In sum, these results indicate the oxidation of 
mitochondrial cysteine residues are significantly increased due to a high fat diet 
in wild type mice, but this is protected against in mice lacking FABP4/aP2. 
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Figure 2:  Loss of FABP4/aP2 in macrophages decreases oxidative 
modification of cysteine residues. (A) Cysteine oxidation in the mitochondrial 
fraction of visceral adipose tissue from C57Bl/6J mice on a chow or high 
saturated fat diet. (B) Cysteine oxidation in the mitochondrial fraction of visceral 
adipose tissue from WT and AKO C57Bl/6J mice maintained on a high saturated 
fat diet. (C) Cysteine oxidation in the whole cell lysate of the stromal vascular 
fraction of the visceral adipose tissue from wild type and FABP4/aP2 null mice 
(WTSVF and AKOSVF). (D) Cysteine oxidation was measured in whole cell lysates 
of WT and AKO macrophage cell lines following a 24 hour treatment with 100 
ng/mL LPS. The intensity of the entire lane for each sample was normalized to 
internal controls ATP5α or β-actin to determine changes in cysteine oxidation, 
and the difference in all experiments were significant by at least p < 0.05. 
Spacing between the blot images in panel C indicates samples from the same 
membrane and exposure but rearranged for presentation purposes.  
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Loss of FABP4/aP2 in the SVF of high fat fed mice leads to upregulation of 
antioxidants and 20S proteasome subunits.  Changes in redox status of cells 
is frequently associated with correlative changes in expression of proteins linked 
to redox biology, particularly anti-oxidants and proteins involved in quality-control 
systems (9, 33-35).  To address this, we evaluated several antioxidants in 
visceral adipose derived SVF in high fat fed WT and AKO mice.  While transcript 
levels of catalase and superoxide dismutase 2 (Sod2) were not significantly 
different between WT and AKO cells (Figure 3A), there was a significant increase 
in the protein expression for both antioxidants in AKO animals (Figure 3B-C). 
Furthermore, the 20S proteasome, which is responsible for recognizing and 
turning over oxidized proteins in an ATP-independent manner, was also 
upregulated in both AKO SVF and the AKO macrophage cell line (Figure 3B-D).  
Finally, in addition to the protection observed in cysteine oxidation, the SVF from 
AKO mice maintained on a high saturated fat diet revealed an upregulation in 
methionine sulfoxide reductase A expression (Figure 3E).  These results 
demonstrate that loss of FABP4/aP2 reprograms the redox biology of 
macrophage cells towards a more reduced environment through two processes; 
reduced hydrogen peroxide production and upregulation of antioxidants and 
quality control systems.   
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Figure 3: Expression of antioxidants and the 20S proteasome in stromal 
vascular cells of FABP4/aP2 null macrophages.  The SVF of visceral adipose 
tissue from high fat fed WT and AKO mice were analyzed for (A) manganese 
Sod2 and catalase mRNA, (B) protein of manganese SOD2,  (C) catalase and 
the αβ subunit of the 20S proteasome.  (D) The AKO and wild type macrophage 
cell lines were analyzed for the expression of PSMB5, the catalytic subunit of the 
20S proteasome.  (E) Methionine sulfoxide reductase (MsrA) levels in the SVF of 
WT and AKO high fat fed mice. Spacing between the western blot images 
indicates samples from the same membrane and exposure but rearranged for 
presentation purposes. (*p < 0.05, **p < 0.005) 
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FABP4/aP2 regulates activation of the mitochondrial unfolded protein 
response.  One of the consequences of a heightened cellular oxidation and 
concomitant protein modification is activation of the unfolded protein response 
(15, 36, 37).  Indeed, oxidative modification of mitochondrial proteins often leads 
to misfolded or aggregated proteins and the increased expression of a cluster of 
proteases (ClpP and LonP1) designated for proteolysis and clearance of aberrant 
polypeptides (37). To test this in the FABP4/aP2 model system, mitochondrial 
unfolded protein response (mtUPR) markers were evaluated in the adipose 
derived stromal vascular fraction isolated from high fat diet fed wild type and 
FABP4/aP2 null mice.  Consistent with the differences in mitochondrial oxidation 
status shown in Figure 2, expression of the mtUPR markers in the AKO derived 
stromal vascular fraction were almost completely ablated compared to that from 
wild type mice (Figure 4A).  Extending this observation from the animal models to 
cell lines, the AKO macrophage cell line also had a significantly reduced mtUPR 
as measured by ClpP and LonP1 (Figure 4B). This protection was also shown to 
be dependent on UCP2 expression as silencing of UCP2 in the AKO 
macrophage cell line led to an increased expression of LonP1, ClpP and Hsp60 
(Figure 4C). Similar to the results in the SVF fraction and AKO cell line, ClpP and 
LonP1 are also significantly decreased in bone marrow derived macrophages 
(BMDMs) isolated from FABP4/aP2 null mice compared to wild type littermate 
controls (Figure 4D). These results indicate that loss of FABP4/aP2 and 
concomitant change in redox environment attenuates the oxidation of 
mitochondrial proteins and the up regulation of the mitochondrial unfolded protein 
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response through expression of UCP2.  Consistent with this, Xu et al., have 
reported that mitochondrial function as measured by cellular respiration and 
responsiveness to LPS challenge is improved in FABP4/aP2 null macrophages 
compared to mitochondria from wild type cells (3). 
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Figure 4: Expression of LonP1, Hsp60 and ClpP in stromal vascular cells, 
BMDMs and macrophage cell lines from FABP4/aP2 null and control mice.  
(A) LonP1, Hsp60 and ClpP in stromal vascular cells from visceral adipose tissue 
of high fat fed WT and AKO mice. (B) LonP1 and ClpP in WT and AKO 
macrophage cells lines. (C) LonP1, Hsp60 and ClpP in AKO-eGFP (AKO-
eGFPMΦ) control and AKO-UCP2 knockdown (AKO-UKDMΦ) macrophages. (D) 
Bone marrow derived macrophages from WT and AKO mice were treated with 
100 ng/mL LPS for 24 hours and LonP1 and ClpP protein levels were measured 
(*p < 0.05, **p < 0.005).  
 
 
	 120				
Maintaining mitochondrial homeostasis through deletion or inhibition of 
FABP4/aP2 prevents inflammasome activation and IL-1β secretion.  
Reducing ROS levels blunt the NF-κB pathway and stabilizes the NF-κB 
inhibitory subunit, IκB-α (38, 39). As shown in Figure 1, hydrogen peroxide is 
significantly reduced in AKO macrophages, prompting us to measure the protein 
level of IκB-α. As expected, the SVF from AKO mice have significantly more IκB-
α compared to WT (Figure 5A).  NF-κB regulates the expression of the 
inflammasome members such as caspase-1, NLRP3 and IL-1β.  Consistent with 
this, caspase-1 protein expression was significantly decreased in AKO 
macrophage cell lines and AKO BMDMs upon LPS stimulation compared to the 
respective WT controls (Figure 5B-D). This was also observed when message 
levels of Nlrp3 were measured in macrophage cell lines and BMDMs.  In both cell 
models, Nlrp3 was significantly decreased when FABP4/aP2 was genetically 
ablated and when pharmacologically inhibited using HTS01037 in BMDMs prior 
to LPS stimulation (Figure E-F). This finding was corroborated at the protein level 
with a significant decrease in NLRP3 protein measured in the AKO cell line 
compared to the WT control (Figure 5G).  NF-κB also regulates the expression of 
the inflammasome substrate, IL-1β, and upon LPS stimulation, WT macrophages 
exhibited an increase in IL-1β transcript levels.  On the other hand, AKO cells 
were protected from this increase in IL-1β message, but the protection was lost 
when UCP2 was silenced (Figure 6A-B).  The reduction in IL-1β was also 
observed in WT BMDMs pre-treated with HTS01037 and AKO BMDMs upon LPS 
treatment (Figure 6C). 
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Figure 5: Genetic ablation of FABP4/aP2 up regulates IκB-α and reduces 
caspase-1 and NLRP3 expression.  (A) Expression of IκB-α in stromal vascular 
cells of visceral adipose from high fat fed WT and AKO mice.  (B) Caspase-1 
mRNA in WT and AKO macrophage cells treated with or without 100 ng/mL LPS 
for 24 hours. (C-D) Caspase-1 protein expression in WT and AKO macrophage 
cell lines and BMDMs following 100 ng/mL LPS for 24 hours. (E) Nlrp3 mRNA in 
WT and AKO macrophages with or without 100 ng/mL LPS for 24 hours and (F) 
measured in WT and AKO BMDMs treated with +/- 30 uM HTS01037 for 4 hours 
followed by +/- 500 ng/mL LPS for 4h hours. (G) NLRP3 protein expression in 
WT and AKO macrophages. (*p < 0.05, **p < 0.005) 
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Figure 6: Decrease in transcript levels of IL-1β in AKO macrophages is 
dependent on expression of UCP2. (A) IL-1β mRNA measured in WT and AKO 
macrophages with or without 100 ng/mL LPS for 24 hours. (B) IL-1β mRNA 
measured in AKO-eGFP control and AKO-UKD macrophages in the same 
conditions as (A) (**p < 0.005, ***p < 0.0005). 
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The bioactive form of IL-1β must be generated by inflammasome-dependent 
cleavage and secretion, which can be triggered by ROS (as well as other 
sources) through the mitochondrial intrinsic apoptotic pathway (22, 40).  To 
assess activation of the inflammasome in the FABP4/aP2 system, IL-1β 
secretion was evaluated in response to either pharmacologic or genetic ablation 
of FABP4/aP2.  Secretion of IL-1β was completely absent in FABP4/aP2 null 
macrophages and wild type macrophages treated with HTS01037 compared to 
wild type controls when treated with LPS and ATP (Figure 7A).  Furthermore, 
inflammasome activation was shown to be partially activated by the mitochondrial 
intrinsic apoptotic pathway, as observed when WT macrophage cells were 
treated with cyclosporine A (CsA) in addition to LPS and ATP stimulation.  As 
shown in Figure 7B, CsA could blunt the secretion of IL-1β.  Conversely, IL-1β 
secretion could be induced in AKO macrophages by inhibiting the proteasome 
with MG132 or by silencing UCP2 (Figure 7C-D), indicating that AKO cells 
maintain some capacity for inflammasome activation through UCP2 expression 
and protein unfolding. Both mitochondrial-induced apoptosis and protein 
unfolding have been shown to activate the inflammasome and may explain the 
upregulation of the 20S proteasome observed in AKO cells (21, 22, 41, 42). 
Consistent with the immortalized cell lines, bone marrow derived macrophages 
from AKO or WT mice pre-treated with HTS01037 exhibited a significant 
decrease in IL-1β secretion upon stimulation with LPS and ATP (Figure 7E).  
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Figure 7: Secretion of IL-1β is reduced under pharmacologic and genetic 
ablation of FABP4/aP2. (A) IL-1β secretion with or without 4 hour treatment of 
30 µM HTS01037 followed by 500 ng/mL LPS for 4 hours followed by 2 mM ATP 
for one hour.  (B) IL-1β secretion in WT macrophages in the presence of 2 µM or 
5 µM cyclosporine A for 1 hour followed by LPS and ATP treatment as described 
in (A).  (C) AKO macrophages treated with LPS and ATP alone as in (A) or with 
the addition of 10 µM MG132 for 2 hour after LPS treatment and IL-1β secretion 
was measured. (D) IL-1β secretion measured after LPS treatment with or without 
ATP as in (A) and compared between AKO-eGFP control and AKO-UKD 
macrophages. (E) IL-1β secretion measured in BMDMs from WT and AKO mice 
(with or without a 4 hour pre-treatment of 30 µM HTS01037) treated for 4 hours 
with 500 ng/mL LPS followed by 2 mM ATP for one hour.  (*p < 0.05, **p < 0.005) 
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DISCUSSION 
Loss of the adipocyte fatty acid-binding protein has been shown to be protective 
against the low-grade chronic inflammation that leads to metabolic dysfunction 
under obese conditions (24, 27). This is largely due to the phenotypic switch of 
adipose tissue macrophages from an inflammatory to anti-inflammatory state with 
concomitant changes in cytokine and chemokine secretion (25, 26). While the 
major physiological outcomes have been described, the molecular mechanisms 
that underlie such regulation have remained enigmatic. Herein, we show for the 
first time the major finding that macrophage redox biology is regulated by the 
FABP4/aP2-UCP2 axis, resulting in changes in protein oxidation and preventing 
the induction of the mitochondrial unfolded protein response and inflammasome 
activation (Figure 8).  
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Figure 8. Schematic representation of the FABP4/aP2-UCP2 axis and 
subsequent regulation of the inflammasome.  Genetic or pharmacologic 
inhibition of FABP4/aP2 increases the level of intracellular free fatty acids (e.g. 
palmitoleic acid).  This in turn leads to increased expression and activation of 
UCP2 that decreases H2O2 levels.  Lowering H2O2 attenuates protein oxidation 
and activation of the mtUPR.  ER-mitochondrion communication activates the 
inflammasome and subsequent IL-1β secretion.  
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We have previously shown that loss of FABP4/aP2 leads to an upregulation of 
UCP2 and Sirt3 in macrophages (3, 28). We now observe that AKO 
macrophages are protected from LPS-induced hydrogen peroxide production, 
and UCP2 regulates this process.  The difference in hydrogen peroxide ultimately 
protects AKO cells from hyper-oxidation of cysteine (and likely methionine) 
residues following 12 weeks of a high fat diet. This was observed in the 
mitochondria and stromal vascular fractions of VAT isolated from AKO mice 
compared to WT mice and further confirmed in immortalized macrophage cell 
lines following LPS stimulation. Interestingly, the difference in cysteine oxidation 
was less dramatic in the cell lines compared to the tissue samples, potentially 
due to different signaling nodes being activated under obese conditions as 
opposed to a single treatment of LPS.  Moreover, protein levels of inflammasome 
complex members and mtUPR markers in Sirt3 silenced macrophage cells are 
not different compared to the wild type cells.  This suggests that changes in the 
mtUPR and inflammasome activation are likely to be independent from Sirt3 but 
are downstream of UCP2 (results not shown).   
 
Because UCP2 is a mitochondrial protein that reduces oxidative stress and 
mitochondrial protein oxidation, we focused on downstream effects potentially 
mediated by the mitochondrial unfolded protein response. Indeed, LonP1, ClpP 
and Hsp60 were markedly reduced both in the AKO SVF, BMDMs and 
macrophage cell lines from AKO mice when compared to controls. This 
protection was also shown to be dependent on the expression of UCP2 as the 
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mitochondrial proteases were increased in UCP2 silenced cells compared to 
eGFP controls in the AKO background.  It is also of interest to note that the most 
robust changes observed in these different cell lines consistently came from 
LonP1, which specifically recognizes and targets oxidized proteins for 
degradation (37). Compromising homeostasis of the mitochondrion can lead to 
apoptosis, and one of the primary downstream effectors of the mtUPR in immune 
cells is the activation on the inflammasome (22, 40, 43, 44). This was prevented 
in cells lacking FABP4/aP2 as observed by the decrease in mRNA and protein 
levels of the inflammasome members as well as its activation (IL-1β secretion). 
The activation of the inflammasome in WT macrophages could be partially 
rescued with CsA, inhibitor of the mitochondrial intrinsic apoptosis pathway, and 
conversely, IL-1β secretion could be induced in AKO cells by inhibiting the 
proteasome or by silencing UCP2 (22). This indicates that both mitochondrial 
integrity and protein folding, potentially through redox status, are maintained 
through the FABP4/aP2-UCP2 axis. Furthermore, this system was also tested in 
BMDMs, and while there was a detectable amount of IL-1β from the AKO and 
WT HTS01037 treated cells, both conditions exhibited a significant decrease 
compared to WT BMDMs following LPS and ATP stimulation (Figure 7).  
 
ER-mitochondrial communication is a dynamic process driven by dedicated 
structural domains within mitochondria-associated membranes ((45-47).   
Previous work by Xu et al. (3) has shown that ER stress is blunted in FABP4/aP2 
ablated macrophage cells due to increased expression of UCP2.  Paralleling this, 
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Bronner et al. demonstrated that ER stress leads to mitochondrial ROS 
production which in turn promotes inflammasome dependent IL-1β secretion 
(16).   These observations suggest that in macrophages, inflammasome 
activation may be potentiated by either ER stress or the mtUPR and that 
organelle communication may facilitate signaling.  The FABP4/aP2-UCP2 axis is 
upstream of these events and implicates redox balance as being pivotal in 
initiating the inflammatory response (Figure 8). 
 
The major regulator of IL-1β expression is mediated through the NF-κB pathway 
and its activation is up regulated through hydrogen peroxide signaling (48, 49).  
Indeed, hydrogen peroxide signaling is essential for full activation of inflammatory 
macrophages, and blunting such processes inhibits NF-κB activation (38, 48, 50, 
51).  Consistent with this, Figure 5 shows that IκB-α, the major inhibitor of NF-κB, 
was upregulated in the SVF of AKO mice.  The mechanism for this up regulation 
is unresolved but may be due to enhanced stability from a less oxidizing 
environment (38, 39). In support of IκB-α upregulation in AKO SVF, NF-κB 
targets, NLRP3 and caspase-1 were decreased in AKO macrophages. IL-1β 
message levels were also decreased in AKO macrophages, and in agreement 
with others studies, was shown to be dependent on UCP2 expression (32). 
Another transcription factor that may be playing a role in altered redox status of 
FABP4/aP2 null cells is nuclear factor (erythroid-derived 2)-like 2 (Nrf-2).  It is the 
master regulator of antioxidants, such as SOD2 and catalase as well as the 20S 
proteasome and UCP2 (42, 52, 53). While the antioxidants and UCP2 are able to 
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decrease hydrogen peroxide, the 20S proteasome is uniquely able to recognize 
and degrade oxidized proteins to prevent subsequent unfolding (41). Determining 
the localization and activation of both NF-κB and Nrf-2 will be an essential next 
step in understanding the role of the FABP4/aP2 – UCP2 axis in controlling 
inflammasome activation in response to obesity.  
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SUMMARY 
The study of metabolic flux changes that occur in response to cellular need has 
been an exciting area of research over the past several years. Macrophages are 
no exception to this, and metabolic alterations have shown to be an obligatory 
process in order to carry out robust inflammatory responses. The mitochondria 
are a particular hot spot of metabolic regulation as reactive oxygen species and 
other key signaling metabolites accumulate here. Itaconate is one such 
metabolite that is produced after an inflammatory stimulus in order to reestablish 
homeostasis, and we have demonstrated this process is regulated by the 
expression of the fatty acid-binding protein 4 (FABP4). While basal expression of 
Irg1 and subsequent production of itaconate are lower in FABP4 knockout 
macrophages compared to wild-type cells, there is a robust increase in Irg1 
levels upon longer treatment of LPS. These data indicate that while FABP4 null 
macrophages are initially less inflammatory and thus require less itaconate, 
these cells have an enhanced compensatory mechanism in which to resolve 
inflammation. 
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INTRODUCTION 
Macrophages are extremely efficient in their ability to respond to local signals in 
their environment. One such way this is accomplished is through altering 
metabolic pathways that produce necessary metabolites for rapid proliferation, 
production of reactive oxygen species (ROS) or inflammatory resolving 
metabolites. This can be accomplished in a variety of ways, such as 
transcriptional control of glycolytic enzymes by HIF-1α that increases glycolytic 
flux in response to inflammatory stimuli (1). Macrophages also alter metabolic 
metabolite levels by regulating mitochondrial dynamics through fission and fusion 
events. During fission, the complexes in the electron transport chain become 
disordered and less compact, increasing the movement of electrons into the 
mitochondrial matrix and ultimately increasing ROS levels (2). This heightened 
oxidative state is required in order to defend against pathogens, but 
macrophages must be able to resolve this inflammation once the infection has 
been cleared. Under resolving conditions, the mitochondria undergo a greater 
rate of fusion events that reorganize the electron transport chain. This allows the 
cell to rely on oxidative phosphorylation instead of glycolysis, reducing ROS 
levels and proliferation.  
 
Another mechanism in which to dampen an inflammatory response is to 
accumulate the metabolite itaconate, which is derived from cis-aconitate in the 
tricarboxylic acid (TCA) cycle by the immune responsive gene 1 (Irg1). 
Transcriptional and metabolomics profiling of bone marrow derived macrophages 
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(BMDMs) under basal and lipopolysaccharide (LPS) conditions showed that Irg1 
expression and itaconate production were two of the most robust changes 
following inflammatory stimulus (3). Based on these data, it was initially 
hypothesized that itaconate was an essential inflammatory marker of an M1 
macrophage. However, itaconate is also known to have antimicrobial affects and 
under further investigation, itaconate production was demonstrated to be 
required for the reduction in IL-1β and IL-18 cytokine secretion in BMDMs (4). 
 
The expression of the fatty acid-binding protein 4 (FABP4) has demonstrated to 
be a positive regulator of macrophage inflammation and subsequent metabolic 
disease. This inflammation can be prevented through genetic knockout or 
pharmacologic inhibition of FABP4 but is lost when the uncoupling protein-2 is 
silenced (5, 6). This led us to hypothesize FABP4 modulates the expression of 
Irg1. In order to test this, FABP4 wild type (WT) and knockout (AKO) 
macrophage cell lines were treated under basal and LPS stimulated conditions 
and Irg1 expression was examined.  
 
MATERIALS AND METHODS 
Mice. Male WT and AKO C57BL/6 mice were maintained on a chow diet 
(BioServe) and fed ad libitum. The hind legs were harvested for bone marrow 
isolation between 8-10 weeks of age. All experimental procedures using animals 
were reviewed and approved by the University of Minnesota Institutional Animal 
Care and Use Committee 
	 141				
Cell culture. Macrophage FABP4/aP2 knockout (AKO), wild type and UCP2 
knockdown in an AKO background were maintained in RPMI 1640 (Invitrogen) 
with 5% fetal bovine serum(5). The macrophages were immortalized from bone 
marrow derived macrophages of chow fed WT and AKO C57BL/6 mice(7). 
Raw264.7 macrophages and UCP2 knockdown Raw264.7 macrophages were 
maintained in DMEM (Invitrogen) with 10% fetal bovine serum (FBS)(5). Bone 
marrow derived macrophages were isolated from WT and AKO C57BL/6 mice 
between 8-10 weeks of age and maintained in Iscoves’s Modified Dulbecco’s 
Medium (Invitrogen), 10% FBS and 10ng/mL macrophage colony-stimulating 
factor (M-CSF) for one week. 2X106 cells were plated in 6-well plates prior to 
LPS stimulation(8). 
 
Quantitative RT-PCR. Total RNA was isolated using TRIzol reagent (Invitrogen) 
from WT, AKO and AKO-UKD macrophage cell lines. cDNA synthesis was 
performed by using iScript according to the manufacturer's protocol (Bio-Rad).  
qRT-PCR amplification utilized a Bio-Rad CFX 96 real-time system with a SYBR 
green Supermix (Bio-Rad). TATA-binding protein (TBP) was used as an internal 
control to normalize expression. Primer sequence for IL-6 are forward: 
CAAGAGATACAAAGAAATGATGG and reverse: 
ACTCCAGAAGACCAGAGGAAAT 
 
Immunoblot analysis. Cells were lysed in radioimmunoprecipitation assay 
(RIPA) buffer supplemented with fresh protease inhibitors. All samples were 
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normalized to protein concentration prior to loading using a bicinchoninic acid 
(BCA) assay. Between 20-50µg of protein was added for each sample and run 
on an SDS-PAGE gel followed by transferring to a polyvinylidene difluoride 
(PVDF) membrane. After blocking with Odyssey blocking buffer (LI-COR 
Biosciences), membranes were incubated with primary antibody overnight at 4° 
C. Membranes were washed and incubated with secondary antibody conjugated 
to Li-Cor IRDye for 1 hr and visualized using Odyssey infrared imaging (Li-Cor 
Biosciences). The primary antibodies used were anti-Irg-1 (Abcam) and anti-β-
actin (Sigma-Aldrich).  
 
Statistical Analysis. All statistics were determined as a result of the standard 
deviation following a two-tailed un-paired student t-test. Experiments were 
carried out in at least three replicates. 
 
RESULTS 
Differential expression levels of Irg1 transcript and protein levels.  
As shown in figure 1A, transcript levels of Irg1 are significantly reduced in AKO 
macrophages under basal conditions. However, following 18 hours of LPS 
stimulation, Irg1 expression in AKO macrophages surpasses that of WT 
macrophages. We next examined Irg1 expression in BMDMs following a 4-hour 
LPS treatment. Interestingly, the AKO Irg1 expression had a decreasing trend 
compared to WT BMDMs (figure 1B). Furthermore, silencing of UCP2 in AKO 
macrophages (AKO-UKD) increased Irg1 expression under basal conditions, but 
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that upregulation was lost following longer time course treatments of LPS for 8 
and 24 hours (figure 1C). 
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Figure 1: Differential expression of Irg1 transcript levels in WT and AKO 
macrophages. (A) Irg1 transcript levels were measured in WT and AKO 
macrophages under basal conditions or following 18 hours 100ng/mL LPS 
treatment. (B) WT and AKO BMDMs were treated with 500ng/mL LPS for 4 hours 
and Irg1 levels were measured. (C) AKO-eGFP and AKO-UKD macrophage cell 
lines were treated with 100ng/mL LPS for the indicated time. All experiments 
were done in replicates of 4 and statistical significance was measured using 
student’s t. test with a *p<0.05, **p<0.005, ***p<0.0005   
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Due to this interesting observation of a time-dependent expression pattern of 
Irg1, WT and AKO macrophages were treated with LPS for 0-12 hours and 
protein levels of Irg1 were assessed. Similarly to the transcript levels, Irg1 protein 
expression was significantly decreased in AKO macrophages under basal 
conditions and up to 4 hours of LPS treatments. However, at 7 hours of LPS 
treatment Irg1 expression was not significantly different between the two cell 
lines, and AKO Irg1 expression ultimately surpassed WT Irg1 at 12 hours LPS 
treatment (Figure 2A). To further determine the affects of acute LPS treatment, 
the small molecular inhibitor of FABP4 (HTS01037) was tested. Pharmacologic 
inhibition recapitulated the AKO phenotype as Irg1 expression was significantly 
reduced when pretreated to WT macrophages followed by a 4 hour LPS 
treatment, but was unchanged in the absence of LPS. This observation in the 
short LPS treatment was further confirmed in BMDMs (Figures 2B-2C). Finally, 
UCP2 was silenced in Raw264.7 macrophages and Irg1 expression was 
measured. Interestingly, there was no difference between control cells (Raw-
eGFP) and UCP2 silenced cells (Raw-UKD) under basal conditions, but Irg1 
expression could not be induced following 18 hours of LPS stimulus in UCP2 
silenced macrophages (Figure 2D). This indicates the enhanced induction of Irg1 
in AKO macrophages following a longer treatment of LPS is partially dependent 
on the presence of UCP2.  
 
 
 
	 146				
Figure 2: LPS stimulated Irg1 protein expression follows a time dependent 
pattern dependent of FABP4 and UCP2 expression. (A) Time course of 
100ng/mL LPS treatment was done in WT and AKO macrophages and Irg1 
protein was quantified. (B) WT macrophages were treated with 30uM HTS01037 
or 100ng/mL LPS alone for 4 hours each or combined with 4 hours HTS 
pretreatment followed by 4 hours LPS treatment. Irg1 expression was quantified 
following cell harvesting (C) WT and AKO BMDMs were treated with 500ng/mL 
LPS for 4 hours. (D) Stable cell lines Raw264.7 macrophages with either e-GFP 
(Raw-eGFP) control vector or UCP2 targeted shRNA (Raw-UKD) were 
developed and Irg1 expression was quantified under basal and 18 hours 
100ng/mL LPS treatment. All experiments were done in replicates of 3 or more 
and statistical significance was measured using student’s t. test with a *p<0.05, 
**p<0.005, ***p<0.0005   
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Itaconate production and itaconate inflammatory regulation in WT and AKO 
macrophages. 
Finally, intracellular itaconate levels were measured in WT, AKO and AKO-UKD 
macrophages. Following the protein expression patterns of Irg1, itaconate 
metabolite concentrations were unchanged when WT macrophages were treated 
with HTS but were significantly reduced in AKO macrophages under basal 
conditions. There was also a small but significant increase in itaconate 
concentrations when UCP2 was silenced in an AKO macrophage (Figure 3A). 
Metabolite levels under different LPS stimuli are still being tested but are 
predicted to reflect Irg1 protein levels.  
 
With the observation of differing itaconate metabolite levels, we next tested the 
biological consequence of exogenous itaconate treatment. To do this, the cell 
permeable dimethyl-itaconate compound was given to WT and AKO 
macrophages under basal or LPS treated conditions and IL-6 transcript levels 
were measured. After a 4-hour LPS treatment WT macrophages exhibited a 
robust increase in IL-6 message levels, which was protected against in AKO 
macrophages. However, when WT cells were pretreated with 250uM itaconate 
for 16 hours, IL-6 message levels were dramatically decreased and comparable 
to IL-6 expression in AKO macrophages (Figure 3B). This indicates the 
production of itaconate is sufficient in blunting the inflammatory IL-6 response in 
macrophages and is being regulated by FABP4 activity.  
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Figure 3: Itaconate levels are decreased in FABP4 null macrophages and 
affects inflammation. (A-B) Cell pellets of WT, AKO, AKO-eGFP and AKO-UKD 
macrophages were submitted for metabolite analysis of itaconate concentrations 
under basal conditions. (C) WT and AKO macrophages were treated with 250uM 
dimethyl-itaconate as indicated for 16 hours followed by treatment of 100ng/mL 
LPS for 6 hours as indicated. The RNA was isolated from these samples and IL-6 
transcript levels were measured. All experiments were done in replicates of 4 and 
statistical significance was measured using student’s t. test with a *p<0.05, 
**p<0.005, ***p<0.0005   
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DISCUSSION 
Macrophages and other immune cells alter their metabolic pathways in order for 
intermediate metabolites to accumulate and help promote an inflammatory 
response. For instance, upon an inflammatory stimulus, macrophages decrease 
the rate of oxidative phosphorylation and succinate accumulates as a result. 
Succinate helps stabilize hypoxia inducible factor-1 alpha (HIF-1α), which in turn 
upregulates various inflammatory cytokines (9). However, while an inflammatory 
response is necessary to eliminate pathogens, homeostasis must be 
reestablished. Recently, it has been determined that Irg-1 expression is initiated 
after an inflammatory response and sequesters cis-aconitate to be metabolized 
to itaconate. This metabolite has demonstrated to be essential in reducing the 
inflammatory profile of macrophages (10).  
 
This polarization of macrophages is required for not only immune function in 
response to infections but also in maintaining the metabolic health in adipose 
tissue. FABP4 has demonstrated to play a critical role in the inflammatory 
phenotype in macrophages and loss of FABP4 in macrophages is able to prevent 
both the low-grade, chronic inflammation and the subsequent metabolic 
dysfunction (11). Here, we show a connection in the differential expression of 
Irg1 in WT and AKO macrophages in a time dependent manner following LPS 
stimulation. While basally, there is less expression of Irg1 and production of 
itaconate in AKO macrophages, Irg1 expression surpasses that of WT 
macrophages after longer LPS exposure. Future work is aimed at measuring the 
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production of itaconate in LPS treated WT and AKO macrophages as well as 
determine the mechanism in which Irg1 expression is initially decreased in AKO 
macrophage but robustly increases after longer exposure to inflammatory 
signals. 
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Obesity in and of itself is not a disease in the traditional sense. With every body 
type and genetic background, the body mass index (the measurement in which 
obesity is defined) will differ between individuals. In fact, not only does the 
adipose tissue specialize in safely storing excess energy in the form of 
triglycerides, but the lack of adipose tissue leads to a wide range of syndromes 
(1-3). Furthermore, the ability to produce more adipocytes (hyperplasia) of a 
smaller size facilitates both lipid storage and exhibits a secretory profile that 
maintains metabolic homeostasis (i.e. IL-10 and adiponectin) independent of 
weight. On the other hand, under obesity-induced metabolic dysfunction, 
adipocytes typically increase in size and are associated with hypoxic conditions 
and inflammatory cytokine production that ultimately shifts the immune cell 
landscape of the tissue (4-6). This inflammatory environment further exacerbates 
conditions, such as insulin resistance and lipotoxicity as the adipocyte begins to 
fail in lipid storage capabilities (2).  
 
It is still unclear as to why some individuals develop metabolic disease as a result 
of obesity while others maintain a relatively normal metabolic profile. While the 
events described above play a role, the mechanisms in which those fates are 
determined are not understood. However, what is clear is that by preventing the 
inflammatory events of the adipose tissue, obesity can be uncoupled from 
diseases, such as insulin resistance, cardiovascular disorders and 
hepatosteatosis (7, 8). For this reason, research has gone in to deciphering the 
secretory factors released by adipocytes that recruit and activate inflammatory 
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immune cells by potentiating essential signaling events of those immune cells. 
Many elements have demonstrated to be critical, including the population of T 
cells, macrophages and Eiosinophils as well as the expression level of various 
proteins.  
 
The fatty acid-binding protein 4 (FABP4) is one such protein that regulates 
phenotypic aspects of adipocytes and macrophages. Over the last twenty years, 
there is no doubt that FABP4 plays a major role in metabolic health, but the 
mechanism in which this occurs in macrophages is still being determined. This 
connection is strongly linked to the activation of inflammatory pathways in 
response to obese conditions and has more recently been associated with the 
production of reactive oxygen species. In addition to the damaging 
characteristics of ROS, it has also been shown to be a major signaling system, 
particularly related to hydrogen peroxide. Through oxidation of cysteine residues, 
hydrogen peroxide can alter enzymatic activity and protein-protein interactions.  
 
One such avenue this thesis work tried but ultimately was unable to uncover 
were the proteins that are particularly susceptible to oxidation under high fat diet 
conditions. As shown in chapter 4, there is a clear increase in global cysteine 
oxidation when mice are put on a high fat diet for 12 weeks, and that is protected 
against in the FABP4 knockout mice. In order to fully understand how these 
oxidizing events alter protein function, stability and interactions, we wanted to 
identify the proteins and quantify the level of cysteine oxidation in wild type 
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versus FABP4 null obese mice. This was attempted using an isotope coded 
affinity tagging technique, but due to the multiple precipitation and solubilizing 
steps, loss of sample was a major challenge (9). However, there are now labeling 
techniques that can covalently bind to sulfenic acids, such as dimedone, which 
has the potential to greatly increase the yield of these experiments and offers the 
possibility to identify those proteins that are targets for oxidation (10).  The 
greatest challenge with this technique would be to develop differentially tagged 
dimedone compounds, so samples could be quantifiably compared between 
different diet and genotype conditions.  
 
Another are of current pursuit following this thesis work is to further elucidate the 
role of itaconate and the regulatory mechanism in an FABP4 deficient system. 
Irg1 synthesizes Itaconate in an extremely robust manner following inflammatory 
stimulation, and it is thought this increased production is to resolve the 
inflammation and return the macrophage to a homeostatic state. As seen in 
chapter 5, there is an interesting observation that basally FABP4 knockout 
macrophages exhibit lower expression levels of Irg1 and production of itaconate 
compared to wild type macrophages. However, after a longer exposure to LPS 
(around 12 hours), Irg1 expression in FABP4 null macrophages exceeds wild 
type macrophages, which still falls in line with the anti-inflammatory nature of an 
AKO macrophage. Since FABP4 is a fatty acid binding protein, we are currently 
looking at the affects of fatty acid treatment in these cells. Preliminary results 
show an increased expression of Irg1 with palmitate treatment and a decreased 
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expression with palmitoleic acid (data not shown). This differential expression 
was also dependent on UCP2, but it did not follow the same pattern as the LPS 
treated macrophages, indicating different signaling pathways between fatty acids 
and LPS (data not shown). With these complex results, work is ongoing to 
answer this question as itaconate has recently been shown to be essential in 
macrophage polarization (11, 12).  
 
In conclusion, the dynamics of cellular organization and signaling is vastly 
complex in the adipose tissue and is highly sensitive to nutrient conditions. While 
this work does not tackle the obesity pandemic, it does aim to answer some of 
the underlying mechanisms in which metabolic syndrome can develop. 
Inflammation has been shown to be a determinant of not only insulin resistance 
but also other inflammatory diseases. By understanding the pathways that 
determine macrophage polarization, there is potential to develop new 
therapeutics to reduce the low-grade chronic inflammation seen in obese adipose 
tissue. This would relieve both a great burden on health care costs as well as the 
cost in quality of life for an individual.  
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